limit
pitfallsin
past
decad
molecular
method
detect
quantif
viru
infect
replac
mani
tradit
viral
cultur
serolog
methodsth
molecular
test
significantli
improv
clinic
turnaround
time
reduc
handson
time
addit
increas
diagnost
sensit
specificitymani
commerci
assay
kit
automat
instrument
avail
allow
mani
clinic
microbiolog
laboratori
offer
molecular
testshowev
routin
implement
nucleic
acid
dna
rna
amplif
hybrid
methodolog
clinic
laboratori
still
associ
number
limitationsincreas
costtest
due
expens
instrument
reagentsamplif
carryov
contaminationstandard
posit
neg
quantit
controlsintegr
coamplifi
intern
dna
control
demonstr
absenc
polymeras
chain
reaction
pcr
inhibitor
amplificationprevent
falseposit
falseneg
report
due
antigen
pathogen
nucleic
acid
sequenc
drift
accur
interpret
data
softwar
analys
specimenscollect
adequ
specimen
import
molecular
diagnosi
viru
specimen
type
commonli
use
molecular
diagnosiswhol
blood
ml
collect
edta
lavend
top
tube
store
freezeplasma
collect
ml
whole
blood
edta
acd
solut
ppt
steril
tube
store
whole
blood
room
temperatur
h
remov
plasma
cell
within
h
collect
centrifug
g
min
clarifi
filtrat
centrifug
store
plasma
within
min
separ
plasma
may
also
store
nonfrostfre
freezer
h
colder
freezer
avail
ship
dri
ice
overnight
deliveri
minimum
volum
specimen
ml
plasmaurin
first
ml
void
urin
collect
steril
urinalysi
contain
ml
steril
screw
cap
tube
prefer
store
less
h
store
long
termbronchi
lavagetrach
aspir
ml
collect
steril
tube
store
less
hbone
marrow
ml
collect
edta
tube
store
freezetissu
tissu
block
collect
steril
screwtop
contain
add
small
amount
salin
keep
moist
avoid
use
viral
transport
media
avoid
potenti
inhibit
pcr
fresh
tissu
store
immedi
preserv
nucleic
acidsparaffinembed
tissu
accept
usual
section
thick
suffici
pcr
analysi
tissu
section
must
deparaffin
xylen
dna
extract
fecal
steril
swab
plastic
shaft
small
fecal
sampl
place
ml
steril
salin
contain
tight
fit
lid
use
viral
transport
media
avoid
potenti
inhibit
pcrswab
steril
swab
plastic
shaft
place
ml
steril
salin
use
viral
transport
media
avoid
potenti
inhibit
pcrcerebrospin
fluid
csf
ml
fluid
submit
steril
leakproof
tube
store
less
h
store
long
term
assay
perform
analysisanalyt
performanceanalyt
sensit
determin
lowest
number
target
detect
assaycrossreact
specif
determin
assay
produc
falseposit
result
presenc
high
concentr
similar
unrel
pathogen
bacteria
yeast
viru
linear
evalu
log
differ
expect
concentr
differ
within
log
ratio
observ
mean
quantit
expect
concentr
within
quantit
rang
measur
concentr
within
linear
rang
good
reproduc
clinic
performancelimit
detect
lowest
concentr
target
nucleic
acid
detect
detect
cutoff
replic
usual
replic
detect
cutoff
point
assay
quantit
scale
neg
specimen
produc
result
cutoff
confidencelimit
quantif
lowest
concentr
target
nucleic
acid
quantifi
replicatesreproduc
reproduc
test
usual
establish
test
three
six
sampl
panel
known
concentr
target
triplic
quadrupl
commerci
panel
use
establish
paramet
avail
reproduc
express
percent
correl
coeffici
quantit
assay
cv
rang
precis
reproduc
test
result
eg
inter
intratechnologist
inter
intraassay
sensit
true
posit
sampl
true
posit
sampl
limit
detectionspecif
true
neg
sampl
true
neg
sampl
limit
detect
qualiti
control
quantit
assay
addit
qualiti
control
procedur
perform
includ
calibr
calibr
verificationcalibr
set
oper
establish
specifi
condit
relationship
reagent
systeminstru
respons
correspond
concentrationact
valu
analyt
calibr
procedur
typic
specifi
method
manufactur
may
also
establish
laboratorycalibr
verif
denot
process
confirm
current
calibr
set
remain
valid
methodrecalibr
calibr
verif
analyt
measur
rang
valid
must
perform
least
everi
monthsfor
run
sensit
control
includ
addit
posit
neg
control
recommend
two
level
control
high
low
includ
human
immunodefici
viru
hiv
rna
retroviru
belong
lentiviru
famili
genet
differ
share
nucleotid
homolog
relat
siv
type
appear
caus
clinic
indistinguish
aid
howev
seem
less
easili
transmit
period
initi
infect
ill
longer
case
worldwid
predomin
viru
gener
peopl
refer
hiv
without
specifi
type
viru
refer
rel
uncommon
concentr
west
africa
rare
found
elsewherestructur
hiv
virion
fig
hiv
viru
consist
spheric
viral
particl
encas
lipid
bilay
deriv
host
cell
cover
protrud
peglik
structur
compos
glycoproteinsth
viru
core
nucleocapsid
contain
major
capsid
protein
two
copi
genom
rna
three
viral
enzym
proteas
revers
transcriptas
integras
viral
replic
fig
first
step
infect
entri
host
cell
requir
bind
molecul
viru
molecul
host
cell
surfac
mediat
molecul
two
surfac
molecul
chemokin
receptor
betachemokin
alphachemokin
also
requir
entryonc
bound
viral
envelop
fuse
cell
membran
viru
rna
enzym
enter
cytoplasmrevers
transcriptas
catalyz
first
synthesi
dna
copi
viral
rna
second
synthesi
second
dna
strand
complementari
first
one
therefor
doublestrand
dna
dsdna
generatedintegras
facilit
integr
viral
dna
cellular
chromosom
cell
divid
provid
latenc
enabl
viru
effect
evad
host
responsestranscript
dna
result
product
rna
rna
serv
genom
new
virus
translat
produc
viral
protein
viral
protein
facilit
proteas
assembl
viral
particl
use
host
cell
proteinmak
machinerycomplet
hiv
particl
assembl
macrophag
hiv
bud
cell
without
ruptur
cell
cycl
begin
cell
hiv
exit
cell
ruptur
effect
kill
cell
gag
pol
env
gene
encod
structur
protein
new
viru
particl
six
gene
tat
rev
nef
vif
vpr
vpu
regul
synthesi
assembl
viral
particlesth
phylogen
analysi
nucleotid
sequenc
env
gene
enabl
classif
three
group
major
n
nonm
outlier
group
infect
classifi
nine
differ
genet
subtyp
infect
belong
group
subtypeclass
b
preval
develop
worldhiv
transmit
via
sexual
contact
blood
via
transfus
blood
product
contamin
needl
passag
mother
child
utero
birth
ingest
breast
milk
although
saliva
contain
small
quantiti
viru
viru
spread
kiss
hiv
spread
rout
aerosol
insect
casual
contact
hiv
caus
agent
acquir
immunodefici
syndrom
aid
lead
caus
death
human
age
yearstwo
main
target
hiv
immun
system
central
nervou
system
hiv
target
cell
monocytesmacrophag
langerhan
cellsdendrit
cell
caus
sever
immunosuppress
neuropatholog
symptom
dementia
mening
encephalopathi
hostcommon
opportunist
infect
pneumocysti
carinii
candidiasi
tuberculosi
cryptococcu
cytomegaloretinitiscommon
malign
kaposi
sarcoma
lymphoma
nonhodgkin
brain
primari
uterin
carcinomaindividu
hiv
face
long
challeng
road
diseas
steadi
natur
histori
start
asymptomat
state
progress
toward
aid
natur
histori
includ
three
phasesearlystag
hiv
infect
defin
presenc
hiv
count
greater
earli
stage
develop
week
initi
exposur
selflimit
flulik
symptom
resolv
week
later
patient
high
level
viral
product
viremia
widespread
seed
lymphoid
tissueschron
phase
hiv
infect
occur
count
chronic
phase
associ
period
latenc
immun
system
intact
continu
hiv
replic
may
last
year
patient
either
asymptomat
develop
persist
lymphadenopathi
minor
opportunist
infect
candidiasi
herp
zosterwhen
count
drop
hiv
infect
enter
crisi
phase
certain
infect
easili
handl
intact
immun
system
take
advantag
immunocompromis
state
opportunist
infect
certain
cancer
may
also
appear
reason
patient
count
less
least
one
opportunist
infect
cancer
specif
seen
crisi
phase
hiv
offici
design
aid
specimen
whole
blood
serum
plasma
tabl
convent
test
problemslymphocyt
cell
also
call
cell
thelper
cell
primari
target
hiv
viru
quantit
cell
first
effect
predictor
hiv
progress
count
one
mani
factor
includ
clinic
statu
hiv
viral
load
medic
adher
assess
start
chang
antiretrovir
arv
treatmentth
cell
count
import
determin
stage
hiv
diseas
indic
need
prophylaxi
opportunist
pathogensmost
laboratori
report
count
part
list
sever
type
lymphocyt
absolut
count
rel
percentag
measur
trend
percentag
addit
absolut
count
must
perform
prior
initi
adjust
arv
treatment
manag
decisionsth
percentag
sometim
use
coordin
absolut
valu
assess
signific
chang
absolut
count
absolut
count
fluctuat
overal
lymphocyt
count
vari
percentag
often
remain
stabl
insignific
fluctuat
cell
cytotox
cell
count
appear
predict
clinic
outcomesfor
monitor
purpos
count
repeat
approxim
everi
month
stabl
untreat
patient
patient
stabl
art
count
check
frequent
accord
clinic
situat
viral
culturealthough
specif
singl
posit
cultur
must
confirm
second
specimenrar
use
due
high
cost
laborintens
less
sensit
antibodi
testingneg
cultur
may
caus
technic
problem
defect
viru
inabl
viru
replic
cultur
serolog
antigenearli
develop
assay
detect
hiv
infect
screen
donat
blood
hivadvantag
detect
hiv
infect
prior
develop
antibodiesdisadvantag
limit
util
due
short
window
time
use
test
unavail
antibodi
screen
assay
qualit
detect
antibodi
hiv
common
way
diagnos
hiv
infect
adult
children
month
oldthes
antibodi
usual
detect
within
week
infectionmost
individu
seroconvert
week
although
may
detect
month
yearsth
window
period
time
infect
develop
antibodi
person
infect
hiv
take
week
bodi
make
antibodi
viru
peopl
develop
antibodi
within
month
infect
although
peopl
take
month
rare
case
take
month
test
posit
gener
repeat
test
hiv
occur
month
signific
concern
recent
hiv
infect
addit
level
viru
blood
high
window
period
peopl
easili
transmit
hivserolog
hiv
antibodi
screen
test
highli
sensit
elisa
rapid
test
home
test
requir
followup
preliminari
posit
specimen
highli
specif
hiv
antibodi
confirmatori
assay
western
blot
fig
elisa
method
common
earliest
develop
antibodi
screen
assayhom
access
test
system
analyz
driedblood
spot
finger
stick
collect
filter
paper
home
sent
test
facilityrapid
test
hiv
assay
detect
antibodi
hiv
within
minut
rapid
test
highli
specif
neg
mean
neg
except
window
period
test
also
highli
sensit
posit
mean
like
hiv
must
confirm
use
western
blot
hiv
diagnosi
confirmatori
antibodi
assay
western
blotgold
standard
hiv
diagnost
testingth
viru
disrupt
individu
protein
separ
molecular
weight
via
differenti
migrat
polyacrylamid
gel
blot
onto
membran
support
hiv
serum
antibodi
patient
allow
bind
protein
membran
support
pattern
reactiv
visibl
readdetect
three
major
proteinsvir
band
core
protein
two
envelop
protein
wb
demonstr
antibodi
two
three
major
band
nonreact
wb
detect
viral
band
fig
repeat
reactiv
elisa
reactiv
confirmatori
assay
report
posit
antibodi
specimen
elisa
repeatedli
reactiv
elisa
nonreact
confirmatori
assay
neg
antibodi
serum
antibodi
bind
combin
viral
band
consid
indetermin
followup
blood
specimen
obtain
month
later
repeat
hiv
antibodi
testingindividu
repeat
indetermin
result
undergo
test
use
molecular
assay
pcrat
least
sensit
specif
screen
assay
although
sensit
detect
earli
seroconversiondisadvantag
laborintens
prone
subject
interpret
costli
screen
assay
altern
antibodi
screen
assay
qualit
us
food
drug
administr
fda
approv
assay
test
bodi
fluid
blood
detect
antibodi
although
sensit
specif
less
reliableutil
test
algorithm
serum
elisa
follow
wb
advantag
noninvas
sampl
collect
increas
safeti
due
lack
needl
dispos
infecti
wast
minimizedor
fluid
oral
mucos
transud
antibodi
detect
significantli
lower
serumurin
interpret
criteria
reactiv
wb
requir
presenc
visibl
band
region
molecular
methodsqualit
assay
viral
identif
assay
recommend
resolv
indetermin
western
blot
resultsdna
pcr
roch
hiv
dna
pcr
test
new
technolog
use
hiv
earli
detect
test
new
hiv
pcr
test
look
dna
copi
hiv
viru
peripher
blood
extrem
accur
sensit
cut
edg
hiv
earli
detect
testingth
averag
window
period
antibodi
test
day
antigen
test
cut
window
period
approxim
day
hiv
dna
test
reduc
period
daysdetect
hiv
dna
peripher
blood
mononuclear
cell
pcr
recommend
children
month
old
born
mothersfalseposit
reaction
common
due
small
amount
background
nois
contaminational
initi
posit
dna
pcr
reaction
must
confirm
second
pcr
test
separ
specimencurr
recommend
detect
infant
born
mother
infect
howev
potenti
falseposit
result
must
still
recognizedplasma
hiv
rnasurrog
marker
hiv
diseas
progressiondur
acut
infect
viral
load
level
high
rang
million
copiesml
detect
seroconversionimport
use
plasma
hiv
rna
assay
antibodywestern
blot
test
establish
diagnosi
acut
primari
infectionslow
level
viru
copiesml
may
indic
falseposit
result
consid
diagnost
primari
hiv
infect
standard
antibodi
test
repeat
quantitativevir
monitor
tabl
fig
amplicor
monitor
test
roch
fda
approv
quantit
rna
plasmastandard
assay
limit
detect
amplicor
monitor
copiesml
use
monitor
patient
arv
therapyultrasensit
assay
low
copiesml
use
monitor
viral
load
copiesml
viral
load
result
copiesml
necessarili
indic
absenc
viral
replic
inhibitori
substanc
may
present
plasma
specimen
lead
neg
fals
low
rna
result
improp
specimen
collect
storag
may
fals
lower
plasma
viral
load
resultsplasma
specimen
collect
use
acd
anticoagul
show
quantit
rna
level
lower
collect
tube
contain
edtaacut
concurr
ill
andor
recent
vaccin
may
caus
transient
rise
viral
loadcalcul
hiv
viremia
amplicor
monitor
ampliprep
test
base
optic
densiti
read
input
qs
copi
lot
specif
provid
kit
standard
sampl
volum
factor
ultrasensit
sampl
volum
factor
optic
densiti
qs
quantit
standard
well
lowest
read
select
calcul
fig
hiv
taqman
test
use
three
ltr
primer
one
famlabel
ltr
probe
conjunct
four
gag
primer
one
famlabel
gag
probe
therefor
offer
primer
probe
use
amplifi
gag
ltr
region
also
provid
diagnost
accuraci
test
result
even
mutat
occur
one
two
region
compens
possibl
mismatch
occur
primerprob
region
also
ensur
enhanc
reliabl
test
result
confid
assess
viral
load
fig
singl
viral
load
test
result
use
criteria
guid
therapeut
decis
intervent
clinic
care
patient
viral
load
result
correl
patient
symptom
clinic
present
cell
countdu
inher
variabl
assay
physiolog
variat
concurr
ill
infect
patient
log
chang
plasma
viral
load
consid
signific
chang
branch
dna
bdna
bayer
versant
rna
assay
bdna
signal
amplif
nucleic
acid
probe
assay
direct
quantit
rna
plasma
individu
use
bayer
system
bdna
analyz
test
quantit
rna
rang
rna
copiesmlbdna
base
seri
hybrid
procedur
follow
enzym
substrat
reaction
basic
principl
procedur
bdna
includ
viral
lysi
overnight
hybrid
viral
nucleic
acid
target
captur
plate
follow
wash
step
serial
addit
probe
allow
signal
amplif
detect
quantificationbdna
method
progress
first
gener
assay
accur
reproduc
rel
insensit
third
gener
bdna
test
accur
reproduc
highli
sensit
autom
laboratori
test
optim
patient
manag
result
evolut
bdna
technolog
fdaapprov
method
detect
quantif
versant
rna
assay
present
patient
blood
disrupt
releas
viral
rna
nucleic
acid
sequencebas
assay
nasba
nuclisen
qt
assay
nuclisen
easyq
assaynasba
sensit
isotherm
transcriptionbas
amplif
system
design
specif
detect
rna
target
nuclisen
qt
fda
approv
ce
mark
nuclisen
qt
nasba
endpoint
electrochemiluminesc
ecl
detect
refin
led
develop
ce
mark
nuclisen
easyq
combin
nasba
amplif
realtim
detect
use
molecular
beacon
util
nuclisen
easyq
analyzerth
nuclisen
easyq
assay
boxtel
netherland
quantit
next
gener
amplif
assay
design
overcom
labor
throughput
obstacl
earlier
assaysrealtim
detect
amplicon
occur
nasba
reaction
follow
primer
exhaust
continu
product
antisens
rna
promot
exponenti
phase
product
amplicon
detect
use
molecular
beacon
oligonucleotid
probe
fluoresc
upon
bind
specif
target
sequenceth
publish
perform
characterist
nuclisen
easyq
assay
show
compar
nuclisen
qt
versant
rna
coba
amplicor
monitor
assay
linear
specif
reproducibilityalthough
plasma
fda
approv
use
csf
lymph
tissu
genit
secret
cellspurifi
nucleic
acid
may
use
molecular
test
sequenc
genotypinggenotyp
resist
test
use
rtpcr
dna
sequenc
techniqu
identifi
presenc
absenc
resist
relat
mutat
viral
arv
approv
treatment
hiv
fig
arv
therapi
slow
replic
hiv
bodi
patient
infect
hiv
current
activ
arv
therapi
patient
viral
load
continu
increas
patient
may
undergo
either
genotyp
phenotyp
resist
testingphenotyp
test
measur
abil
viru
grow
differ
concentr
drug
artifici
condit
laboratori
although
phenotyp
direct
measur
resist
complex
genotyp
therefor
slower
costli
performgenotyp
test
detect
viral
sequenc
chang
sequenc
entir
hiv
proteas
codon
hivrt
codon
cover
known
drug
resist
mutationsno
consensu
genotyp
versu
phenotyp
howev
anticip
genotyp
use
often
greater
access
lower
cost
faster
turnaround
time
mechan
resistancehiv
highli
polymorph
g
viru
quasispeci
replic
convert
rna
dna
action
viral
revers
transcriptas
enzym
rt
rt
enzym
littl
proofread
correct
capac
therefor
error
incorpor
provir
dna
replic
time
error
concis
drug
bind
site
provid
select
advantag
viru
presenc
arv
drugsth
resist
viru
predomin
subsequ
increas
viral
load
howev
extent
resist
implic
choic
therapi
determin
read
sequenc
gene
encod
proteas
rt
enzymestak
medic
exactli
prescrib
import
part
avoid
resist
miss
dose
take
time
lower
amount
arv
chemic
bodi
mean
viru
properli
suppress
viru
abl
replic
faster
increas
chanc
becom
resistantresist
arv
limit
futur
treatment
option
hiv
resist
one
drug
sometim
resist
similar
drug
group
call
crossresist
mean
arv
drug
work
even
use
indic
drugresist
patient
acut
recent
infectiontherapi
failur
includ
suboptim
treatment
respons
treatment
chang
consideredpregn
women
pediatr
patient
detect
viral
load
treatment
initi
chang
consideredtransmit
drugresist
viru
common
area
like
detect
earlier
cours
hiv
infect
consid
resist
test
earlier
cours
infect
one
fdaapprov
assay
dna
sequenc
genotyp
opengen
dna
sequenc
system
bayer
healthcar
berkeley
cait
twostep
procedur
first
amplifi
proteas
revers
transcriptas
region
genom
use
rtpcrthe
amplifi
dna
sequenc
yield
nucleotid
profil
viru
use
sequenc
gelonc
sequenc
gener
compar
wildtyp
sequenc
differ
confer
drug
resist
highlight
anoth
fdaapprov
assay
dna
sequenc
genotyp
system
celera
diagnost
alameda
ca
distribut
abbott
laboratori
abbott
park
il
twostep
procedur
first
amplifi
proteas
revers
transcriptas
region
genom
use
rtpcr
cycl
sequencingth
amplifi
dna
sequenc
yield
nucleotid
profil
viru
use
capillari
electrophoresisth
minimum
input
viral
rna
assay
copiesml
use
ml
plasma
success
genotyp
pitfal
genotypinggenotyp
variant
compris
less
sampl
may
detect
genotyp
result
reflect
predomin
subtypeinterpret
genotyp
result
base
clade
b
preval
clade
develop
world
howev
subtyp
recombin
may
undetectedassess
resist
complic
replic
kinet
resist
mutant
resist
mutant
often
less
fit
wildtyp
viru
may
becom
undetect
select
drug
nevertheless
mutant
persist
patient
select
drug
pressur
reappli
mutant
replic
resist
popul
quickli
predomin
plasma
hiv
rna
surrog
marker
hiv
diseas
progress
use
guid
monitor
therapi
managementarv
therapi
implement
patient
follow
clinic
find
symptomat
hiv
infect
aidsdefin
condit
count
viral
load
copiesml
pregnant
mother
copiesml
initi
highli
activ
antiretrovir
therapi
haart
goal
arv
patient
attain
viral
load
copiesml
includ
ration
sequenc
arv
agent
achiev
maximum
possibl
viral
replic
suppressionin
arv
patient
patient
success
treatment
regimen
monitor
viral
load
measur
baselin
everi
week
initi
everi
month
maxim
suppress
attain
although
patient
count
may
requir
less
frequent
viral
load
monitoringtyp
patient
begin
therapi
chang
therapi
result
virolog
failur
viral
load
measur
week
therapi
initi
decreas
least
log
indic
effect
therapi
patient
reach
goal
copiesml
within
month
absent
incomplet
respons
viral
load
arv
therapi
rais
concern
poor
patient
adher
therapi
andor
viral
resistanceif
signific
increas
increas
viral
load
without
clear
explan
viral
load
repeat
confirm
virolog
failuregenotyp
resist
test
perform
prior
initi
treatment
arv
patient
patient
copiesml
nonrespons
arvgenotyp
resist
test
recommend
patient
copiesml
less
discontinu
arv
therapi
year
hepat
c
viru
hcv
first
recogn
nona
nonb
hepat
viru
nanbh
first
identifi
use
molecular
method
hcv
major
caus
nona
nonb
hepat
affect
world
populationth
common
rout
transmiss
via
blood
blood
product
ie
immun
globulin
surgeri
intraven
drug
abus
significantli
reduc
advent
routin
blood
screen
sexual
transmiss
well
vertic
mother
infant
occur
rate
vertic
transmiss
hcv
hcv
posit
sens
singlestrand
rna
viru
repres
third
genu
famili
flavivirida
genom
encod
singl
open
read
frame
code
structur
one
core
two
envelop
protein
well
seri
nonstructur
protein
fig
untransl
region
constant
use
hcv
rna
assay
genotypingcor
region
constant
use
genotyp
assay
core
protein
assay
riba
testsenvelop
region
hypervari
region
associ
high
rate
mutat
region
code
region
code
proteasehelicas
riba
test
found
region
antigen
use
antihcv
riba
test
target
region
code
interferon
respons
region
code
rna
polymeras
antigen
use
antihcv
riba
test
target
area
hcv
consist
heterogen
group
genotyp
base
sequenc
homolog
untransl
region
current
type
subtyp
type
distribut
worldwid
type
respons
approxim
infect
type
occur
primarili
middl
east
type
south
africa
type
hong
kong
unit
state
us
approxim
peopl
infect
hcv
genotyp
other
type
genotyp
common
us
littl
differ
mode
transmiss
natur
histori
infect
among
differ
genotypescur
rate
antivir
therapi
notabl
higher
genotyp
durat
hcv
therapi
shorter
genotypesinfect
hcv
curabl
therapi
current
standard
treatment
base
combin
pegyl
interferon
alpha
ifna
ribavirin
viru
erad
character
sustain
virolog
respons
ie
undetect
hcv
rna
week
treatment
complet
achiev
patient
infect
hcv
genotyp
approxim
patient
infect
genotyp
outcom
therapi
influenc
sever
paramet
includ
treatment
schedul
diseas
characterist
viral
factor
recent
identifi
genet
factor
includ
singl
nucleotid
polymorph
locat
upstream
gene
encod
micrornatarget
therapi
suggest
potenti
mean
combat
viru
current
use
prior
isol
viru
hepat
infect
hcv
previous
known
nona
nonb
hepatitisin
us
approxim
four
million
expos
viru
three
million
chronic
carriersacut
infect
usual
asymptomat
patient
develop
acut
hepat
jaundic
abnorm
liver
function
fig
hcv
rna
detect
blood
within
week
present
onset
symptomsantibodi
hcv
detect
enzym
immunoassay
eia
patient
onset
symptom
increas
month
rna
chronic
infect
patient
eventu
develop
chronic
infect
andor
chronic
hepat
fig
persist
hcv
infect
diagnos
detect
hcv
rna
blood
least
monthsth
import
sequela
chronic
hcv
infect
progress
liver
fibrosi
lead
cirrhosi
endstag
liver
diseas
hepatocellular
carcinoma
hcc
patient
often
asymptomat
nonspecif
symptom
fatigu
malais
abdomin
discomfortmild
moder
elev
alt
sgpt
ast
sgot
asymptomat
patient
normal
liver
enzymesa
mani
normal
level
initi
evaluationmay
posit
hcv
antibodi
test
despit
normal
liver
patient
eventu
develop
cirrhosi
take
decad
occur
sever
liver
cirrhosi
correl
liver
enzym
evalu
liver
biopsyal
etiolog
cirrhosi
increas
risk
patient
cirrhosi
annual
risk
develop
hccapproxim
patient
die
year
hcvrelat
liver
diseas
specimen
blood
plasma
serumcollect
sampl
edta
plasmarapid
separ
serum
plasma
cell
recommend
centrifug
within
h
collectionunsepar
edta
plasma
stabl
room
temperatur
h
collectionsepar
serum
plasma
stabl
room
temperatur
day
refriger
temperatur
week
frozen
year
convent
test
problemsserolog
studiesenzym
immunoassay
eia
detect
hcv
antibodi
recommend
initi
test
identif
hcv
use
screen
risk
populationseia
compar
inexpens
reproduc
carri
high
sensit
specif
eia
detect
antibodi
averag
week
infect
howev
window
period
patient
detect
viral
rna
undetect
level
antibodiesa
neg
enzym
immunoassay
usual
suffici
exclud
diagnosi
hcv
infect
immunocompet
patientshowev
test
fals
neg
immunodefici
endstag
renal
diseaseconvers
falseposit
eia
may
occur
patient
autoimmun
disord
patient
assay
hcv
rna
necessari
diagnosi
chronic
infectiononc
patient
seroconvert
usual
remain
posit
hcv
antibodi
thu
presenc
hcv
antibodi
may
reflect
remot
recent
infectionth
immunoblot
assay
still
use
supplement
assay
person
screen
nonclin
set
person
posit
eia
test
neg
hcv
rnaother
hcv
antibodi
assay
includ
antihcv
igm
assay
avid
test
signific
presenc
antihcv
igm
hcv
infect
unclear
antihcv
igm
report
patient
acut
hcv
patient
chronic
hcvtherefor
antihcv
igm
use
reliabl
marker
acut
hcv
infect
far
igm
assay
use
clinic
practic
howev
increas
serial
measur
antihcv
igm
titer
earli
onset
symptom
may
help
identifi
patient
acut
hcv
altern
increas
antihcv
igg
avid
index
within
week
onset
clinic
symptom
also
report
indic
acut
hcv
infect
paramet
could
use
togeth
antihcv
seroconvers
occur
baselin
sampl
avail
confirm
diagnosi
acut
infect
total
hcv
core
antigen
enzymelink
immunosorb
assay
elisa
hcv
assay
ortho
diagnost
detect
quantif
total
core
antigen
bloodth
hcv
core
protein
highli
antigen
induc
specif
cellular
humor
respons
probabl
play
pivot
role
pathogenesi
hcv
infect
avail
anticor
monoclon
antibodi
allow
develop
elisa
detect
hcv
core
ag
peripher
blood
patient
hcvit
test
posit
antihcv
antibodi
prospect
lowrisk
popul
screeningtot
hcv
core
antigen
elisa
quantit
ortho
clinic
diagnost
sensit
close
pcr
assay
diagnos
acut
hcv
infect
window
period
hcv
antibodi
develop
also
use
monitor
respons
antivir
treatmentth
elisa
hcv
use
three
recombin
antigen
origin
four
region
viral
genom
core
assay
quantit
immunoassay
total
free
antibodi
bound
hcv
nucleocapsid
core
antigen
assay
use
captur
elisa
format
differ
two
assay
elisa
hcv
assay
step
assay
disrupt
immun
complex
present
sampl
assay
intend
use
test
hcv
core
antigen
either
preseroconvers
acut
postseroconvers
chronic
phase
hcv
infectionless
expens
less
prone
carryov
pcr
test
use
rough
screen
correl
hcv
rna
load
howev
less
sensit
pcrbase
assay
individu
variat
highersimilar
technolog
use
architect
hcv
assay
abbot
laboratori
analyt
sensit
recent
develop
architect
hcv
assay
abbott
laboratori
abbott
park
il
vari
accord
hcv
genotyp
intern
unit
hcv
rna
per
millilit
iuml
drawback
total
hcv
core
ag
elisa
lower
limit
detect
hcvposit
patient
dialysi
often
low
hcv
rna
level
recombin
immunoblot
assay
riba
riba
develop
simultan
detect
antihcv
antibodi
hcv
core
antigenriba
use
confirm
eia
result
sinc
earli
gener
high
rate
fals
positivesthird
gener
riba
riba
develop
test
hcv
includ
protein
earlier
gener
high
specificitya
new
combin
assay
develop
licens
europ
monolisa
hcv
agab
ultra
biorad
marn
la
coquett
franc
monolisa
hcv
agab
ultra
base
combin
indirect
test
antibodi
sandwich
test
ag
detect
molecular
methodsqualit
tabl
qualit
hcv
rna
test
use
confirm
hcv
diagnosi
follow
posit
indetermin
antibodi
test
result
differenti
resolv
activ
infect
may
use
detect
acut
infect
prior
seroconvers
especi
use
confirm
diagnosi
peopl
indetermin
hcv
immunoblot
riba
result
well
immunosuppress
immunoincompet
individualsrecommend
sensit
test
hcv
rna
qualit
assay
genprob
target
amplif
base
sequenc
nc
region
hcv
genomeamplif
hcv
rna
via
transcriptionmedi
amplif
method
tma
detect
limit
tma
iuml
amplicor
hcv
test
coba
amplicor
hcv
test
roch
use
primer
amplifi
sequenc
within
highli
conserv
utr
hcv
genomelimit
detect
ul
iuml
depend
genotyp
ie
use
centrifug
ultracolumn
qiagen
process
larg
volum
ml
lod
improv
quantit
tabl
averag
unitsml
less
sensit
qualit
testsus
establish
baselin
viral
load
prior
therapi
monitor
chang
viral
load
therapypcr
two
realtim
pcr
platform
current
avail
detect
quantif
hcv
rna
coba
taqman
platform
use
togeth
autom
sampl
prepar
coba
ampliprep
system
roch
molecular
system
pleasanton
ca
abbott
platform
abbott
diagnost
chicago
il
use
amplif
platform
togeth
devic
sampl
prepar
art
lower
limit
detect
iuml
art
iuml
capctmvers
hcv
rna
quantiplex
assay
bdna
bayer
signal
amplif
direct
nc
region
core
region
hcv
genomemicrowel
plate
formatequival
detect
genotyp
hcv
rna
copiesml
hcv
rna
copiesiu
broad
dynam
rang
iuml
compar
evalu
bayer
bdna
roch
pcr
viral
load
assay
demonstr
pcr
report
signific
lower
viral
load
much
higher
rang
hcv
rna
detect
quantif
use
clinic
practic
diagnos
chronic
hcv
infect
identifi
patient
need
antivir
therapi
monitor
virolog
respons
antivir
therapi
document
treatment
failur
genotypingtrugen
hcv
nc
genotyp
kit
bayer
healthcar
llc
berkeley
california
techniqu
util
pcr
fragment
previous
gener
diagnost
roch
amplicor
hcv
testsimultan
pcr
amplif
direct
sequenc
clip
sequenc
noncod
region
ncr
versant
hcv
genotyp
assay
lipa
bayer
healthcar
llc
innolipa
hcv
ii
method
use
typespecif
oligonucleotid
probe
attach
nitrocellulos
strip
detect
sequenc
variat
found
nc
region
hcvthe
biotinlabel
pcr
product
hybrid
probe
strip
stringent
condit
hybrid
wash
streptavidinlabel
alkalin
phosphatas
ad
follow
incub
chromogen
result
develop
purplebrown
precipit
match
probe
biotinyl
pcr
producthybrid
amplicon
one
line
strip
allow
classif
six
major
genotyp
common
subtyp
third
wave
technolog
invad
assay
third
wave
technolog
madison
wisconsin
new
dnascan
method
applic
term
cleavas
fragment
length
polymorph
cflp
reli
format
uniqu
secondari
structur
result
dna
allow
cool
follow
brief
heat
denatur
serv
substrat
structurespecif
cleavas
enzym
gener
set
cleavag
productsform
secondari
structur
sensit
nucleotid
sequencesth
presenc
sequenc
polymorph
result
gener
uniqu
collect
cleavag
product
structur
fingerprintsit
target
wellconserv
ncr
hcv
determin
hcv
genotyp
need
initi
therapi
pegyl
ifna
ribavirin
determin
dose
ribavirin
treatment
durat
requir
hcv
resist
testingsever
amino
acid
substitut
confer
resist
directli
act
antivir
molecul
proteas
inhibitor
identifi
case
failur
tripl
combin
pegyl
ifna
ribavirin
either
telaprevir
boceprevir
hcv
variant
resist
compound
selecteddirect
sequenc
analysi
revers
hybrid
method
use
identifi
amino
acid
substitut
confer
resist
antivir
drugsultradeep
sequenc
method
pyrosequenc
detect
minor
resist
popul
hcv
genosur
repres
first
seri
hcv
drug
resist
assay
develop
monogram
bioscienc
support
clinic
evalu
hcv
directact
antivir
daa
agent
use
manag
hcv
infect
hcv
genosur
analyz
genet
sequenc
nonstructur
protein
hcv
genotyp
encod
enzym
essenti
viral
replic
assay
detect
mutat
specif
identifi
associ
boceprevir
telaprevir
resist
pitfallsit
import
note
genotyp
bia
possibl
hcv
molecular
assay
extens
genet
heterogen
virusfalseposit
result
due
contamin
detect
neg
control
falseneg
result
due
amplif
inhibit
detect
intern
control
due
loss
bacteria
specimen
prepar
home
brew
pcr
assay
standard
variat
sampl
handl
laboratori
method
affect
sensit
assay
hcv
test
use
highrisk
patient
intraven
drug
user
children
born
hcvposit
mother
hivposit
patient
figur
show
algorithm
hcv
testingpati
suspect
chronic
hcv
infect
test
hcv
antibodi
patient
suspect
acut
infect
test
hcv
antibodi
also
hcv
rna
realtim
pcr
analysi
hcv
rna
repeat
patient
undergo
treatment
better
adjust
use
therapeut
agentshcv
rna
test
perform
inpati
posit
antihcv
testpati
antivir
treatment
consid
use
quantit
assaypati
unexplain
liver
diseas
whose
antihcv
test
neg
immun
compromis
suspect
acut
hcv
infect
hcv
genotyp
determin
hcvinfect
individu
prior
treatment
order
determin
durat
therapi
likelihood
respons
genotyp
analysi
shown
amino
acid
substitut
correl
resist
therapi
commerci
test
yet
avail
although
home
brew
kit
madeth
treatment
choic
peginterferon
plu
ribavirin
hepat
b
viru
hbv
envelop
dsdna
hepadnaviru
spheric
viru
three
import
polypeptid
hbv
surfac
antigen
hbsag
envelop
protein
hbv
core
antigen
hbcag
core
protein
hbv
e
antigen
hbeag
earli
protein
nonstructur
protein
code
core
gene
envelop
protein
involv
viral
bind
releas
suscept
cell
inner
capsid
reloc
dna
genom
cell
nucleu
viral
mrna
transcribedhbv
circular
partial
doublestrand
dna
viru
approxim
nucleotid
highli
compact
genom
contain
four
open
read
frame
encod
envelop
core
core
precor
polymeras
x
protein
fig
although
hepatocyt
suscept
infect
cell
type
may
affect
lesser
extent
life
cycl
hbv
begin
attach
cell
surfac
cytoplasm
dna
still
core
capsid
remov
dna
pass
nucleu
form
coval
close
circular
dna
cccdna
hbv
use
host
transcript
machineri
replic
gene
use
rna
polymeras
ii
host
strand
cccdna
act
templat
transcript
transcript
mrna
translat
host
protein
synthesi
machineri
form
viral
protein
endoplasm
reticulum
protein
assembl
virion
secretedhbv
recogn
endem
china
part
asia
onethird
world
popul
activ
infect
hbvhbv
strain
classifi
least
hbv
genotyp
j
sever
subtyp
base
nucleotid
homolog
surfac
gene
except
newli
identifi
genotyp
j
geograph
ethnic
distribut
hbv
genotyp
subtyp
well
character
genotyp
mainli
found
northwestern
europ
subtyp
north
america
africa
subtyp
wherea
genotyp
b
c
describ
southeastern
asian
popul
present
genotyp
b
divid
subtyp
among
isol
japan
found
east
asia
found
indigen
popul
live
arctic
alaska
northern
canada
greenland
genotyp
c
includ
subtyp
mainli
exist
east
southeast
asia
genotyp
e
f
seen
east
africa
new
world
respect
genotyp
often
found
southern
europ
part
central
asia
india
africa
middl
east
genotyp
g
recent
determin
genotyp
franc
america
germani
genotyp
h
report
patient
central
america
recent
genotyp
novel
intergenotyp
recombin
among
genotyp
c
g
isol
vietnam
lao
newest
hbv
genotyp
j
identifi
ryukyu
island
japan
genotyp
close
relationship
gibbonorangutan
genotyp
human
genotyp
cacut
infect
genotyp
result
higher
rate
chronic
genotyp
b
c
compar
genotyp
b
case
patient
genotyp
c
lower
rate
spontan
hbv
e
antigen
hbeag
seroconvers
occur
tend
delay
hepat
genotyp
c
lower
respons
rate
genotyp
b
genotyp
c
also
associ
sever
liver
diseas
includ
hepatocellular
carcinomath
rate
new
hbv
infect
declin
approxim
sinc
nation
strategi
elimin
hbv
infect
implement
us
declin
greatest
among
children
born
sinc
routin
vaccin
children
first
recommend
transmit
parenter
sexual
contamin
open
cut
mucou
membran
long
incub
period
day
fig
asian
patient
like
vertic
infect
mother
child
african
western
patientsmajor
affect
patient
recov
ill
character
byanorexia
nausea
vomit
headach
fever
abdomin
pain
dark
urin
sometim
jaundiceelev
transaminas
hyperbilirubinemia
elev
alkalin
phosphatas
may
also
occurextrahepat
manifest
includ
arthralgia
arthriti
nephriti
dermat
patient
continu
carri
viru
marker
activ
viral
infect
greater
month
initi
infectionsmal
percentag
may
develop
chronic
persist
hepat
sequenc
fibrosi
cirrhosisincid
hcc
increas
viral
genom
found
integr
cellular
dna
casesmay
associ
polyarter
cryoglobulinemia
recent
sever
clinic
score
system
nomogram
consist
previous
confirm
independ
risk
predictor
sex
age
famili
histori
hcc
alcohol
consumpt
serum
alanin
aminotransferas
alt
level
hbeag
statu
serum
hbv
dna
level
andor
hbv
genotyp
introduc
easytous
nomogram
base
noninvas
clinic
characterist
found
accur
predict
hcc
risk
either
commun
hospitalbas
hbvinfect
person
specimen
whole
blood
serum
plasmaconvent
test
problemsserolog
studiesvir
antigen
particl
fig
dane
particledsdna
bilay
mm
diamet
nm
corerar
identifi
infecti
serumthought
infecti
viru
particl
hbsagind
prior
hbv
exposureloc
surfac
dane
particleprevi
known
australia
antigen
hbcagrepres
acut
chronic
nm
core
dane
particl
hbeagmark
hbv
infectionpres
hbsagposit
patientsstrong
correl
larg
serum
concentr
dane
particl
hbsaghbeag
associ
high
infect
antibodi
fig
antihbsantibodi
surfac
antigendetect
disappear
hbsagprotect
properti
antihbcantibodi
core
antigendetect
appear
hbsagus
confirm
hbv
infect
hbsag
antihb
absent
window
phase
antihbeantibodi
hbeag
antigen
protect
propertiesassoci
low
risk
infect
presenc
hbsag
interpret
hbv
serolog
test
result
tabl
molecular
methodsqualitativecoba
ampliscreen
test
roch
molecular
diagnost
detect
hbv
dna
human
plasmait
intend
use
screen
donor
hbv
dnadetect
limit
copiesmlit
target
gene
quantitativeus
establish
baselin
viral
load
prior
therapi
monitor
chang
viral
load
therapydigen
hbv
dna
hybrid
captur
iidetect
quantit
hbv
dna
serumlimit
detect
hbv
dna
copiesmlquantit
rang
hbv
copiesml
pcr
amplicor
hbv
monitor
semiautom
coba
hbv
amplicor
monitor
test
roch
detect
quantit
hbv
dna
serum
plasmaus
primer
amplifi
sequenc
within
highli
conserv
precorecor
region
hbv
genomeamplifi
genotyp
e
equal
reduc
amplif
genotyp
f
glimit
detect
copiesmlquantit
rang
copiesml
realtim
pcr
lightcyclerfret
hybrid
probesit
target
fragment
gene
quantit
rang
copiesml
realtim
pcr
roch
taqman
assayutil
fret
technolog
probe
base
detect
amplicon
temperatur
cyclingit
target
genelimit
detect
copiesmlquantit
rang
hbv
iuml
copiesml
iu
copi
bdna
assay
versant
hepat
b
viru
dna
assay
bayer
corpor
signal
amplif
direct
nc
region
core
region
hcv
genomemicrowel
plate
formatlimit
detect
copiesmlquantit
rang
hbv
dna
copiesmlequival
detect
genotyp
f
genotyp
mutat
analysi
current
use
mainli
epidemiolog
purpos
rare
need
clinic
purposeslin
probe
assaylipa
innolipa
hbv
genotyp
assay
innogenet
nv
ghent
belgiumthi
method
base
revers
hybrid
principl
biotinyl
amplicon
hybrid
specif
oligonucleotid
probe
immobil
parallel
line
membranebas
strip
amplifi
region
analyz
overlap
sequenc
encod
major
hydrophil
region
hbsag
hbv
genotyp
kit
bayer
corpor
sequenc
phylogenet
analysi
region
hbv
genomeidentifi
hbv
genotyp
drug
resist
mutat
antihb
escap
mutat
base
comparison
dna
sequenc
pitfallsth
analyt
sensit
specif
current
realtim
pcr
assay
allow
accur
quantif
rang
approxim
log
suffici
quantifi
high
hbv
dna
level
found
certain
hbvinfect
patient
necessit
retest
sampl
dilut
factor
quantif
errorsequ
quantif
hbv
genotyp
robust
quantif
case
nucleotid
polymorph
valid
current
commerci
realtim
pcr
assaysther
current
uniform
tendenc
report
hbv
dna
level
standard
unit
copiesml
genom
equivalentsml
iuml
assay
current
regist
use
plasma
serumno
precis
threshold
hbv
dna
establish
could
guid
medic
decis
viral
load
test
use
assess
monitor
respons
therapi
hbv
infect
fig
hbv
carrier
activ
liver
diseas
hbv
dna
load
measur
assess
patient
regard
need
either
interferon
alpha
lamivudin
dna
polymeras
inhibitor
antivir
therapi
also
monitor
effectivenessan
increas
hbv
viral
load
also
use
marker
emerg
lamivudineresist
viral
mutantsact
chronic
infect
hbv
treat
lamivudin
requir
surveil
emerg
lamivudineresist
viral
mutant
lamivudin
monotherapi
point
mutat
activ
site
polymeras
gene
ymdd
variant
occur
frequenc
year
phase
iii
studi
asian
patient
year
therapi
respect
emerg
lamivudin
resist
detect
rise
hbv
viral
load
confirm
sequenc
activ
site
dna
polymeras
geneth
presenc
hbv
precor
mutant
may
caus
activ
liver
diseas
despit
absenc
hbeag
common
marker
activ
hepat
hbv
infect
may
due
either
prematur
stop
codon
point
mutat
precor
gene
mutat
basal
core
promot
region
downregul
hbeag
product
reliabl
detect
genotyp
cytomegaloviru
cmv
viral
genu
viral
group
known
herpesvirida
herpesvirus
share
number
characterist
chicken
pox
variou
herp
virus
viru
ebv
speci
infect
human
commonli
known
human
cmv
hcmv
human
herpesviru
hhv
largest
hhv
character
kb
doublestrand
linear
dna
viru
fig
hexagon
protein
capsomer
surround
three
distinct
layer
matrix
tegument
capsid
outer
envelopecmv
resid
latent
salivari
gland
cell
endothelium
macrophag
lymphocyt
cmv
infect
asymptomaticth
viru
act
block
cell
apoptosi
via
mitochondri
pathway
caus
massiv
cell
enlarg
sourc
viru
nameclin
symptomat
patient
infant
immunocompromis
adult
infant
mode
transmiss
mother
via
placenta
deliveri
breastfeedingfor
adult
cmv
transmiss
occur
close
contact
individu
excret
viru
saliva
urin
bodili
fluid
transmiss
cmv
report
blood
transfus
organ
transplantbi
age
approxim
individu
infect
cmv
age
popul
expos
virushuman
cmv
difficult
cultur
slowli
grow
human
fibroblast
sinc
cmv
specif
term
speci
cell
type
infect
cmv
elicit
humor
cellular
immun
respons
cmv
present
primari
latent
reactiv
reinfectioncmv
transmit
direct
persontoperson
contact
person
excret
viru
saliva
urin
bodi
fluid
contact
infecti
bodi
fluid
eg
urin
diaper
contact
fomit
eg
child
toy
infecti
viru
cmv
sexual
transmit
also
transmit
via
transplant
organ
blood
transfus
infecti
cmv
may
shed
bodili
fluid
previous
infect
person
thu
may
found
urin
saliva
blood
tear
semen
breast
milk
shed
viru
may
take
place
intermitt
without
detect
signsth
incid
primari
cmv
infect
pregnant
women
us
vari
healthi
pregnant
women
special
risk
diseas
cmv
infect
infect
cmv
peopl
symptom
diseas
resembl
mononucleosi
sever
lifethreaten
immunocompromis
patient
includ
organ
recipi
aid
patient
develop
unborn
babi
may
risk
congenit
cmv
diseas
occur
newborn
infant
develop
complic
school
age
cmv
remain
import
caus
congenit
viral
infect
usin
infant
young
children
typic
featur
infect
includ
hepatosplenomegali
extramedullari
cutan
erythropoiesi
thrombocytopenia
petechi
hemorrhag
enceph
often
lead
sever
mental
motor
retardationfor
immunocompromis
patient
cmv
diseas
aggress
condit
cmv
hepat
caus
fulmin
liver
failur
cmv
infect
also
caus
cmv
retin
cmv
coliti
specimenswhol
blood
urin
csf
amniot
fluid
bone
marrow
biopsi
convent
test
tabl
cmv
cytolog
histolog
testsgeneralth
cmv
cytolog
histolog
examin
detect
within
cell
evid
cmv
urin
bodi
fluid
tissu
also
call
cmv
inclus
bodi
detect
use
evalu
manag
cmv
infectionth
cmv
cytolog
histolog
diagnosi
often
consid
gold
standard
diagnos
endorgan
diseas
convent
h
e
stain
reveal
enlarg
cytomegal
cell
often
two
fourfold
larger
surround
cell
usual
larg
eosinophil
intranuclear
inclus
sometim
surround
clear
halo
smaller
cytoplasm
inclus
sensit
show
rang
wide
import
note
patient
gastrointestin
cmv
diseas
fail
demonstr
inclusionsimmunohistochemistri
monoclon
antibodi
direct
cmv
immedi
earli
antigen
increas
diagnost
yield
cmv
compar
routin
h
e
stain
sensit
immunohistochemistri
detect
cmv
infect
approxim
advantagesspecif
definit
diagnosisconfirm
endorgan
diseas
along
viru
infect
diagnosi
pitfallsinvas
procedur
requiredinsensit
viral
cultureconvent
culturevir
cultur
tradit
method
viru
detect
demonstr
viremia
sometim
establish
endorgan
diseas
convent
cmv
cultur
involv
isol
viru
fibroblast
tissu
cultur
produc
distinct
cytopathogen
effect
easili
confirm
fluoresc
antibodi
stainspres
viru
posit
cultur
often
determin
littl
day
cultur
neg
viru
must
held
week
confirm
absenc
cmv
viru
may
present
low
number
origin
sampl
andor
cmv
strain
may
slowgrowingcmv
cultur
perform
blood
tissu
urin
saliva
respiratori
swab
blood
cultur
sensit
high
specif
approach
detect
diseas
cmv
detect
blood
strongli
associ
diseas
detect
urin
saliva
posit
predict
valu
advantagesgold
standard
test
cmv
detection
recov
virus
specimen
pitfallslow
sensit
compar
newer
techniqu
antigenemia
pcr
nucleic
acid
probelack
viru
quantitationa
long
incub
period
week
lack
viru
quantitationfalseneg
result
cell
cultur
inocul
delay
shell
vial
assayanoth
cmv
cultur
shell
vial
cultur
method
rapid
viral
cultur
shell
vial
cultur
immunofluoresc
stain
use
earli
diagnosi
cmv
infectionin
immunocompromis
patient
sensit
specif
claimedspecimen
centrifug
fibroblast
monolay
incub
briefli
stain
fluoresc
monoclon
antibodi
earli
antigen
appear
cytopathogen
effect
result
avail
much
earlier
convent
cmv
cultur
usual
within
hthe
cell
read
fluoresc
microscopeadvantageshigh
sensit
convent
methodsquantit
shell
vial
cultur
avail
wide
use
pitfallsmay
need
larg
amount
biomass
viru
recoveri
serolog
studiescmv
antibodi
testingantibodi
test
use
determin
someon
recent
past
exposur
two
type
cmv
antibodi
produc
respons
cmv
infect
igm
igg
one
may
detect
bloodigm
antibodi
first
produc
bodi
respons
cmv
infect
cmv
igm
antibodi
detect
within
week
two
primari
infect
last
month
sever
month
level
cmv
igm
antibodi
usual
fall
detect
levelsit
detect
recurr
infect
except
immunocompromis
patient
detect
third
casescmv
igg
antibodi
produc
earli
primari
infect
provid
protect
primari
infect
level
igg
rise
activ
infect
stabil
cmv
infect
resolv
viru
becom
inact
person
expos
cmv
measur
amount
cmv
igg
antibodi
blood
rest
lifecmv
igg
avid
test
distinguish
primari
cmv
infect
past
recurr
infect
reactiv
reinfect
cmv
igg
avid
low
primari
infectionprenat
diagnosi
congenit
cmv
infect
perform
case
primari
matern
infect
transplacent
transmiss
cmv
higher
primari
matern
cmv
infect
wherea
low
case
recurr
infect
cmv
igg
antibodi
test
use
along
igm
test
help
confirm
presenc
recent
previou
cmv
infect
cmv
antigenemia
testthi
test
base
upon
detect
structur
protein
express
surfac
infect
polymorph
nuclear
lymphocytesth
specimen
must
process
within
h
collect
result
avail
within
hthe
number
infect
leukocyt
present
report
correl
sever
infectionthi
test
usual
appli
blood
cerebrospin
fluid
sensit
specif
commerci
kitth
cmv
turbo
antigenemia
kit
use
welldefin
antibodi
cocktail
detect
cmv
lower
matrix
phosphoprotein
earli
antigen
viru
replic
abundantli
present
antigenposit
polymorphonuclear
cellsth
cmv
brite
turbo
kit
rapid
new
version
first
fdaregist
immunofluoresc
antigenemia
kit
vitro
cmv
diagnosi
advantagesinexpens
kit
commerci
availablemay
abl
detect
cmv
develop
symptom
pitfallslaborintensiverequir
skill
personnelsubject
interpretationalthough
improv
cmv
viral
cultur
techniqu
semiquantit
read
result
somewhat
subjectivepoor
sensit
urin
sampl
assay
advers
affect
low
leukocyt
count
molecular
method
tabl
generalcmv
dna
test
qualit
quantit
two
major
techniqu
use
hybrid
captur
pcr
pcr
appear
sensit
hybrid
capturediffer
tissu
bodi
fluid
compart
use
pcr
includ
whole
blood
plasma
leukocyt
buffi
coat
specimen
bronchoalveolar
lavag
bal
fluid
target
organ
tissu
stool
whole
blood
pcr
test
sensit
plasma
pcr
testinghigh
cmv
viral
load
seem
correl
symptomat
diseasestool
cmv
dna
test
techniqu
noninvas
would
detect
infect
even
locat
right
colon
reach
sigmoidoscop
examin
stool
cmv
dna
also
possibl
sensit
blood
cmv
dna
detect
colon
diseas
organ
specificcmv
dna
test
blood
promis
techniqu
diagnos
cmv
diseas
advantag
includ
quick
result
h
high
sensit
qualitativecmv
dna
hybrid
captur
assay
digen
fda
clearedth
digen
hybrid
captur
cmv
test
molecular
assay
detect
presenc
cmv
dna
white
blood
cell
blood
collect
edta
sensit
cmv
cultur
sensit
specif
compar
cmv
antigenemia
assay
detect
cmv
viremiaunlabel
cmv
probe
hybrid
viral
dna
immobil
solid
phase
measur
conjug
antihybrid
antibodi
cmv
mrna
nasbaassay
cmv
mrna
nucleic
acid
sequencebas
amplif
nasba
investig
detect
activ
viral
gene
express
replicationcmvspecif
mrna
may
specif
marker
cmv
cultur
dna
pcr
sinc
would
theoret
indic
cmv
replicationsinc
late
transcript
mrna
reflect
complet
replic
cycl
cmv
could
indic
diseasenuclisen
cmv
assay
organon
teknika
inc
durham
nc
fdaclear
test
nuclisen
cmv
measur
replic
cmv
blood
use
nasba
rna
amplif
technologythi
assay
detect
messeng
rna
code
matrix
tegument
protein
cmv
true
late
protein
express
viral
replicationth
nasba
technolog
select
amplifi
rna
dna
background
allow
direct
test
whole
bloodit
direct
rout
diagnos
activ
cmv
infect
monitor
treatment
efficaci
quantitativepcramplicor
cmv
monitor
test
roch
molecular
system
quantit
microtiterbas
pcr
assaycmv
viral
dna
specimen
quantit
coamplifi
region
cmv
dna
polymeras
gene
presenc
known
quantiti
quantit
standardth
primer
use
specif
cmv
polymeras
gene
amplifi
fragment
genean
intern
quantit
standard
qs
ad
known
concentr
specimen
process
extract
recoveri
dna
addit
amplif
detect
monitoredth
lower
limit
sensit
assay
copiesml
plasma
linear
rang
assay
copi
cmv
dna
per
mlthe
inher
sensit
molecular
detect
cmv
pose
problem
sinc
latent
cmv
genom
present
seroposit
individu
may
detect
therefor
critic
adjust
sensit
pcr
latent
genom
detect
advantagessensit
enough
detect
viru
symptom
developmentspecimen
could
store
transportedrapid
less
expens
pitfallsfals
positivecontamin
must
prevent
realtim
pcrthe
cmv
test
realtim
pcrbase
quantit
assay
cmv
dna
detect
human
plasma
use
ampliprep
instrument
autom
specimen
process
analyz
analyz
autom
amplif
detect
test
quantit
cmv
dna
rang
copiesmlvari
home
brew
method
develop
either
use
realtim
taqman
pcr
abi
prism
realtim
lightcycl
pcradvantagesquick
result
turnaround
time
realtim
pcr
assay
hhigh
sensitivitycmv
dna
test
also
greater
concord
cmv
antigen
test
result
also
ad
benefit
increas
specimen
stabil
smaller
requir
specimen
volum
abil
perform
patient
depress
white
blood
cell
count
result
pitfallsfalseposit
result
due
contamin
detect
neg
control
falseneg
result
due
amplif
inhibit
detect
intern
control
due
loss
bacteria
specimen
preparationther
lack
standard
process
differ
techniqu
assay
differ
quantit
method
differ
tissu
blood
compart
test
thu
make
interpret
result
across
studi
challeng
quantit
pcr
sensit
qualit
pcr
cmv
dna
valu
obtain
inhous
quantit
assay
higher
commerci
assaydiffer
quantit
method
includ
report
result
genom
copiesml
copiesml
copiesmicrogram
total
dna
leukocyt
leukocyt
vari
quantit
method
make
comparison
result
almost
impossibleno
clearli
defin
cutoff
valu
determin
cmv
diseas
method
low
specif
low
posit
predict
valu
cmv
cutoff
plasma
rang
copiesml
cmv
dna
antivir
suscept
test
cmv
isolatesgeneralresist
cmv
antivir
major
clinic
problem
patient
aid
current
market
anticmv
drug
name
ganciclovir
gcv
oral
prodrug
valganciclovir
vgcv
foscarnet
fo
cidofovir
cdv
target
viral
dna
polymerasecmv
infect
remain
major
problem
transplant
resist
antivir
encount
form
transplantationin
gener
take
week
month
cmv
develop
resist
antivir
patient
aid
studi
show
preval
resist
ganciclovir
month
therapi
similar
time
cours
found
foscarnet
cidofovir
phenotyp
methodsplaqu
reduct
assayth
gold
standard
antivir
suscept
test
cmv
plaqu
reduct
assayin
assay
standard
inoculum
stock
viru
inocul
cultur
incub
presenc
antivir
agentth
cultur
observ
presenc
viral
plaquesth
agent
isol
defin
concentr
agent
caus
reduct
number
plaqu
producedplaqu
reduct
assay
laborintensiveplaqu
reduct
assay
limit
excess
time
requir
complet
assay
week
lack
standard
method
valid
across
differ
laboratoriesin
addit
repeat
passag
isol
prepar
viral
stock
may
influenc
result
assay
select
cmv
strain
repres
origin
popul
virus
dna
hybrid
assaywhol
genom
dna
extract
transfer
capillari
action
onto
neg
charg
nylon
membran
incub
specif
agentth
membran
hybrid
human
cmv
probe
diagnost
hybrid
athen
ohio
rins
wash
count
gamma
countermean
hybrid
valu
count
per
minut
cpm
concentr
antivir
agent
calcul
express
percentag
cpm
control
culturesth
defin
concentr
antivir
agent
result
reduct
viral
nucleic
acid
hybrid
valu
ie
dna
synthesi
compar
hybrid
valu
controlsdisadvantag
dna
hybrid
assay
requir
use
radiolabel
probesdna
hybrid
assay
advantag
plaqu
reduct
assay
elimin
variat
due
subject
error
result
plaqu
count
differ
individu
viral
load
assay
eg
antigenemia
quantit
dna
cmv
viral
load
assay
may
rise
indic
antivir
resist
factor
includ
complianc
declin
immun
function
may
responsibleth
assay
measur
viral
dna
concentr
expos
rang
drug
concentr
grown
day
presenc
absenc
drug
determinedquantit
antigenemia
assay
less
exact
quantit
polymeras
chain
reactionin
mani
patient
certain
cmv
diseas
eg
gastrointestin
diseas
retin
alway
associ
measur
viral
load
phenotyp
method
viral
product
measur
use
immunofluoresc
immunoperoxidas
elisa
flow
cytometrybas
method
detect
quantit
cell
express
cmv
antigen
earli
late
genotyp
methodsgeneralvir
kinas
dna
polymeras
gene
mutat
welldocu
mechan
resist
current
antiviralsth
mutat
viral
phosphotransferas
gene
code
sequenc
may
confer
resist
ganciclovir
gcv
one
seven
canon
mutat
found
gcvresist
clinic
cmv
strainsalthough
mutat
affect
suscept
fo
cdv
mutat
confer
resist
current
drug
may
emerg
prolong
gcv
therapi
increas
level
resist
confer
preexist
mutat
mutat
often
accompani
mutat
show
higher
level
resist
ganciclovir
possibl
crossresist
foscarnet
andor
cidofovirth
viral
polymeras
gene
occur
region
codon
fig
genotyp
cmv
antivir
resistancedetect
mutat
base
pcr
amplif
specif
region
genom
follow
restrict
enzym
analysi
direct
sequenc
amplif
productstandard
dideoxi
sequenc
detect
emerg
resist
mutat
exce
approxim
sequenc
populationpyrosequenc
report
detect
mutant
subpopul
approxim
level
codon
short
sequenc
read
unsuit
analyz
full
rang
codon
need
genotyp
diagnosi
eg
codon
codon
addit
method
realtim
pcr
melt
curv
assay
also
detect
drug
resist
mutat
advantag
low
copi
number
without
cell
cultur
detect
mix
viru
popul
analyz
semiquantit
multiplex
reaction
differ
mutat
detect
simultan
disadvantag
polymorph
near
known
mutat
may
affect
melt
curv
give
falseposit
result
differ
probe
need
identifi
mutat
codon
besid
assay
may
abl
differenti
differ
point
mutat
occur
codon
attata
gtg
quantit
pcr
determin
cmv
viral
load
solid
organ
transplant
recipi
predict
cmv
diseas
relaps
tabl
well
initi
antivir
therapyvir
load
test
patient
hiv
infect
current
use
predict
cmv
diseas
monitor
efficaci
treatmentpitfallsus
restrict
enzym
analysi
present
confirm
resist
mutat
accompani
alter
known
restrict
enzym
recognit
site
lead
falseneg
result
base
chang
associ
drug
resist
produc
new
restrict
site
lead
falseposit
resultspcr
assay
standard
variat
sampl
handl
laboratori
method
affect
sensit
assaywelldefin
cmv
dna
standard
need
avoid
variat
viral
load
valu
obtain
commerci
home
brew
assay
clinic
util
standard
autom
sequenc
method
character
mutat
associ
drug
resist
offer
routin
genotyp
resist
test
time
frame
impact
clinic
care
ebv
dsdna
viru
herp
famili
hhv
type
character
icosahedr
capsid
glycoproteincontain
envelop
one
common
virus
humanth
genom
linear
dsdna
molecul
kbp
viral
genom
normal
integr
cellular
dna
form
circular
episom
resid
nucleusmost
common
mode
transmiss
ebv
exposur
infect
saliva
asymptomat
individu
viru
rel
fragil
surviv
long
outsid
human
host
fluid
primari
infect
viru
occur
oral
transmiss
asymptomat
individu
ebv
preferenti
infect
b
lymphocyt
remain
latent
affect
populationth
genom
larg
enough
code
protein
identifi
protein
character
thu
far
fall
follow
group
latent
protein
includ
eb
viral
nuclear
antigen
complex
ebna
latent
membran
protein
lmp
termin
protein
lymphocytedetect
membran
antigen
lydma
lytic
cycl
protein
includ
membran
antigen
earli
antigen
complex
ea
viral
capsid
antigen
complex
vca
critic
viral
target
gene
fig
ebv
caus
infecti
mononucleosi
acut
selflimit
diseas
affect
children
young
adult
primari
infect
viru
persist
indefinit
b
lymphocyt
reactiv
cellular
immun
impairedin
infect
young
children
remain
asymptomat
develop
nonspecif
viral
illnessebv
caus
infecti
mononucleosi
associ
ptld
link
sever
malign
nasopharyng
carcinoma
npc
among
chines
male
burkitt
lymphoma
bl
children
central
africanew
guinea
hivinfect
individu
ebv
associ
diseas
oral
hairi
leukoplakia
aidsrel
nonhodgkin
lymphoma
ebv
might
impli
higher
risk
autoimmun
diseas
system
lupu
erythematosu
sle
multipl
sclerosisebv
ubiquit
viru
caus
persist
latent
infect
reactiv
adult
popul
estim
demonstr
serolog
evid
prior
exposur
ebvprimari
infect
young
children
often
asymptomat
caus
nonspecif
minor
illnessfor
adolesc
young
adult
primari
infect
typic
manifest
infecti
mononucleosi
im
usual
selflimit
condit
character
fever
sore
throat
myalgia
lymphadenopathi
hepatosplenomegalya
strong
associ
ebv
burkitt
lymphoma
children
central
africanew
guinea
nasopharyng
carcinoma
among
chines
malesin
hivinfect
individu
ebv
associ
diseas
oral
hairi
leukoplakia
aidsrel
nonhodgkin
lymphoma
ie
oral
hairi
leukoplakia
cn
lymphomapati
undergo
transplant
prone
develop
posttranspl
lymphoprolif
diseas
ptld
although
correl
ebv
burden
diseas
statu
incomplet
understood
sever
studi
shown
associ
symptomat
infect
elev
dna
load
clinic
sampl
increas
viru
burden
also
believ
rapid
indic
immunopatholog
chang
preced
andor
underli
b
lymphocytedriven
chang
caus
ebv
therefor
determin
ebv
dna
load
ebvrel
disord
immunocompromis
popul
import
step
toward
diseas
diagnosi
manag
treatment
specimenswhol
blood
plasma
csf
biopsi
convent
test
problem
tabl
ebv
antibodi
ebv
antibodi
use
help
diagnos
mono
peopl
symptomat
neg
mono
test
ebv
antibodi
includ
viral
capsid
antigen
vca
igm
vcaigg
earli
antigen
ead
detect
current
recent
infect
vcaigg
nuclear
antigen
ebna
detect
previou
infectionheterophil
igm
antibodypres
adult
cours
illnessnonspecif
serolog
respons
ebv
infect
classic
testmeasur
agglutin
sheep
rbc
patient
serum
limit
falseposit
agglutinin
sera
normal
individu
forssman
agglutinin
patient
serum
sick
etc
monospot
test
detect
agglutinin
formal
hors
rbc
remov
prior
absorpt
guinea
pig
kidneyvir
capsid
antigen
antibodi
fig
igm
indic
recent
infect
last
weeksigg
peak
week
infect
persist
year
entir
lifetim
earli
antigen
antibodi
antiddiffus
nuclear
cytoplasm
stain
infect
cellspres
infecti
mononucleosi
patientspersist
monthsdetect
patient
nasopharyng
carcinoma
earli
antigen
antibodi
antirstain
cytoplasm
aggregatesfound
atyp
protract
case
infecti
mononucleosisfound
patient
african
burkitt
lymphoma
nuclear
antigen
antibodyappear
week
infectionpersist
lifefound
patient
burkitt
lymphoma
molecular
method
tabl
situ
hybrid
biogenex
san
ramon
ca
use
tissu
biopsyth
ebv
eber
probe
specif
eber
rna
transcript
intend
detect
latent
ebv
infectionth
ebv
ipst
dna
probe
specif
ipst
repeat
sequenc
ebv
intend
detect
activ
ebv
infect
quantit
competit
pcrspecif
primer
specif
design
ebv
viral
latent
membran
protein
intern
competitor
dna
ssdna
confirm
known
number
namalwa
cell
b
cell
lymphoma
cell
line
contain
two
integr
copi
ebv
genom
per
cell
four
separ
pcr
reaction
tube
contain
intern
competitor
dna
place
competit
ebvspecif
primer
amplif
patient
dnapcr
amplicon
examin
electrophoresi
agaros
gel
visual
use
gel
imag
document
system
band
densiti
quantit
measur
use
biorad
quantiti
one
softwar
use
calcul
ebv
copiesalthough
highli
accur
reproduc
assay
rather
labori
requir
intens
postpcr
handl
sampl
spike
differ
amount
intern
standard
achiev
precis
quantif
realtim
ebv
quantit
kit
roch
detect
lmp
gene
ebv
viral
genomeebv
amplifi
specif
primer
pcr
reaction
amplicon
detect
fluoresc
use
specif
pair
hybrid
probesa
melt
curv
analysi
perform
pcr
run
differenti
posit
sampl
nonebv
speci
ie
herp
viru
familyth
intern
control
synthet
doublestrand
dna
molecul
primer
bind
site
ident
ebv
target
sequenc
compris
uniqu
hybrid
probe
bind
region
differenti
intern
control
targetspecif
amplicon
ad
alreadi
lyse
sampl
purif
step
copurifiedamplifi
ebv
dna
specimen
pcr
reaction
dual
color
detect
kit
allow
quantif
rang
copi
per
reaction
lower
detect
limit
kit
copi
per
reaction
confid
interv
probit
analysi
commerci
assay
reagentsoth
commerci
assay
reagent
includ
nanogen
ebv
qpcr
alert
argen
ebv
qiagen
ebv
lc
rg
pcr
kit
cepheid
ebv
trender
elitechepoch
ebv
asr
quantif
ltdthe
rang
ebv
pcr
target
includ
bamhiwamplif
platform
includ
roch
system
appli
fast
ht
fast
realtim
pcr
system
agil
quantit
pcr
system
qiagen
q
cepheid
ii
realtim
pcr
use
sybr
green
dyeto
maxim
detect
rate
reduc
falseneg
result
two
primer
set
target
highli
conserv
ebv
region
nuclear
antigen
bamhi
fragment
h
rightward
open
read
frame
use
detect
measur
absolut
ebv
dna
load
clinic
set
differ
ebvassoci
diseas
two
separ
realtim
quantit
pcr
assay
use
sybr
green
dye
singl
quantif
standard
contain
two
ebv
genespcr
product
analyz
amplif
curv
melt
analys
amplif
efficiencyth
lower
limit
detect
ebv
region
copiesmlsensit
costeffect
pitfallsquantit
pcr
requir
analysi
absolut
lymphocyt
count
invers
affect
viremia
realtim
pcr
notimport
note
realtim
pcr
assay
requir
sequenti
analysi
run
data
prior
result
report
prevent
fals
posit
ie
pseudoamplif
amplif
nonebv
speci
fals
neg
ie
shift
melt
curv
ebv
variant
pcr
assay
standard
variat
sampl
handl
laboratori
method
affect
sensit
assay
serial
viral
load
test
use
monitor
diseas
burden
assess
efficaci
immunosuppress
therapi
posttranspl
patientsdetect
ebv
tissu
biopsi
assist
diagnosi
ebvrel
malign
includ
lymphoma
nasopharyng
carcinoma
famili
envelop
icosahedr
nucleocapsid
virus
total
nine
membersherp
simplex
viru
hsp
type
type
demonstr
dna
homolog
proteincod
regionsth
genet
map
two
virus
colinear
genom
approxim
size
kbp
kbphuman
known
reservoirdirect
contact
lesion
secret
necessari
transmiss
direct
exposur
infecti
materi
ie
saliva
genit
secret
initi
viral
replic
occur
either
skin
mucou
membran
entri
site
typic
epitheli
common
acquir
earli
life
usual
associ
oral
lesion
acquir
onset
sexual
activ
associ
genit
lesion
viral
type
caus
genit
infect
mayb
clinic
indistinguishablerisk
transmiss
hsv
hsvinfect
mother
vagin
deliveri
infant
estim
birthsbeyond
neonat
period
childhood
hsv
infect
caus
seropreval
antibodi
increas
age
age
year
increas
occur
age
year
individu
seropositivelat
infect
resid
neuron
trigemin
sacral
vagal
ganglia
activ
stimulu
eg
physic
emot
stress
fever
ultraviolet
light
caus
reactiv
viru
form
skin
vesicl
mucos
ulcer
symptom
less
sever
primari
infect
primari
infect
usual
day
incub
periodcutan
vesicl
character
ulcer
eventu
pustul
dri
crust
mucos
vesicl
appear
shallow
punctuat
ulcer
often
coalesceprimari
herpet
gingivostomatitispharyngotonsil
case
asymptomat
case
month
year
character
gener
malais
fever
linear
gingiv
lymphadenopathyprimari
herp
genitali
genit
infect
twice
like
reactiv
recur
time
frequent
genit
infect
classic
vesicular
rash
may
note
progress
lesion
pustul
pain
ulcer
lesion
lesion
may
persist
mani
week
pain
inguin
lymphadenopathi
dysuria
vagin
discharg
frequent
complaint
primari
genit
hsv
infect
asymptomat
seroposit
individu
histori
symptomat
genit
herp
hsv
transmit
presenc
absenc
symptomsprimari
cutan
herpet
infect
occur
wrestler
rugbi
player
contamin
abras
herpet
gladiatorum
scrumpox
hsv
kerat
present
acut
onset
pain
blur
vision
chemosi
conjunct
characterist
dendrit
lesion
corneahsv
case
asept
mening
recurr
episodeshsv
account
case
sporad
viral
enceph
us
clinic
hallmark
hsv
enceph
acut
onset
fever
focal
neurolog
especi
tempor
lobe
symptom
clinic
differenti
hsv
enceph
viral
encephalitid
focal
infect
noninfecti
process
difficultneon
week
highest
frequenc
viscer
andor
cn
infect
hsvinfect
patient
popul
hsv
infect
viscer
organ
usual
result
viremia
multipl
organ
involv
commonrecurr
infect
site
primari
infectionactiv
latent
viru
form
neuron
cervic
ganglia
herp
labiali
sacral
ganglia
selfinocul
finger
thumb
herpet
whitlow
occur
children
orofaci
herp
although
less
commonantivir
prophylaxi
recommend
persist
recurr
casessom
case
erythema
multiform
em
believ
repres
allerg
respons
recurr
hsv
infect
specimensvesicular
fluid
ulcer
lesion
pharyng
throat
swab
urin
csf
autopsi
biopsi
materi
ocular
exud
vagin
swabsspecimen
best
collect
within
first
day
appear
lesion
day
convent
test
problemsvir
cultureconventionalcel
cultur
requir
collect
live
viru
sampl
requir
special
care
transport
laboratori
retain
viabil
viabl
sampl
use
cultur
highli
specif
type
perform
posit
result
gener
reliableth
sensit
cultur
declin
rapidli
lesion
begin
heal
reason
frequent
nonposit
result
fals
neg
typespecif
serolog
test
use
case
confirm
clinic
diagnosi
genit
herpesmani
commerci
cell
line
use
rk
ml
hnk
etc
diagnos
observ
cytopath
effect
cpe
induc
viru
usual
occur
week
initi
inocul
shell
vial
assaya
centrifugationenhanc
cultur
techniqu
use
obtain
rapid
cultur
result
gener
less
sensit
convent
cultureth
test
detect
hsv
shell
vial
cultur
cell
develop
cytopath
effect
precp
immunofluoresc
assay
ifa
stain
shell
vial
viral
detect
type
cytologyintranuclear
inclus
bodiesmultinucl
mold
giant
cellsmargin
nuclear
chromatinind
presenc
herpesviru
varicella
zoster
viru
vzv
exclud
coxsackieviru
nonvir
entiti
serolog
studieslimit
crossreact
antigen
fluid
sampl
use
hsvspecif
antibodi
bound
solid
surfaceantibodi
captur
antigen
antihsv
antibodi
label
enzym
ad
attach
bound
antigen
caus
color
chang
ifa
immunoperoxidas
ipa
assaydetect
hsv
antigen
smear
tissu
hsvspecif
antibodi
label
fluoresc
dye
enzym
peroxidas
label
antibodi
incub
specimen
bind
hsv
antigen
specimen
presentattach
fluoresc
dye
enzym
visual
appropri
region
infect
cell
microscopeus
conjunct
shell
vial
cultur
enzymelink
viru
induc
system
techniqu
combin
cell
cultur
amplif
hsvactiv
report
genesth
test
produc
result
equal
convent
cultur
molecular
methodsrealtim
pcr
detect
kit
roch
detect
differenti
amplifi
specif
primer
pcr
reaction
amplicon
detect
fluoresc
use
specif
pair
hybrid
probesa
melt
curv
analysi
perform
pcr
run
differenti
posit
sampl
melt
point
significantli
differ
wherea
allow
clear
determin
hsv
typeth
intern
control
ad
alreadi
lyse
sampl
purif
step
copurifiedamplifi
hsv
dna
specimen
pcr
reaction
dual
color
detect
realtim
pcr
pcr
kit
abbott
molecular
pcr
kit
detect
differenti
hsv
dna
use
pcr
abi
sequenc
detect
system
appli
biosystem
hsv
tm
master
contain
reagent
enzym
specif
amplif
region
hsv
genometh
amplicon
detect
measur
fam
fluoresc
ned
fluoresc
abi
sdsin
addit
pcr
kit
contain
second
heterolog
amplif
system
identifi
possibl
pcr
inhibit
detect
intern
control
ic
measur
vic
fluorescenceextern
posit
control
lcrgtm
qs
lcrgtm
qs
use
allow
determin
pathogen
load
advantageshsv
realtim
pcrbase
assay
highli
sensit
specif
detect
viru
even
low
viral
sheddingpcrbas
techniqu
shown
increas
overal
rate
hsv
detect
even
patient
visibl
genit
ulcer
pcr
detect
infect
viru
cultur
sensit
specificityth
lower
limit
detect
analyt
sensit
hsv
qualit
pcr
copiesreact
copiesml
sensit
pcrhsv
skin
lesion
sensit
specif
csf
sensit
hsv
detect
frequent
pcr
viral
cultur
regardless
whether
sampl
obtain
hsv
lesion
genit
oral
secret
period
subclin
shed
yield
viru
posit
four
time
greater
pcr
cultur
result
reliabl
especi
set
transport
climat
may
interfer
yield
viral
culturedu
sensit
pcr
mani
lab
offer
pcr
test
cultur
use
sensit
test
neededcsf
posit
first
recurr
episodesmultiplex
pcr
could
perform
vzv
cmv
sampl
pitfallsimport
note
pcr
assay
standard
variat
sampl
handl
laboratori
method
affect
sensit
assaypcr
alway
diagnos
hsv
enceph
first
day
ill
serial
evalu
csf
pcr
first
week
ill
necessari
diagnosi
herp
enceph
neonat
immunocompromis
patient
detect
hsv
csfcsf
pcr
hsv
dna
perform
patient
febril
encephalopathi
even
absenc
focal
featur
initi
csf
pleocytosi
abnorm
ct
mild
atyp
hsv
enceph
may
associ
infect
addit
csf
specimen
use
pcr
includ
mucos
secret
skin
lesion
etccurr
treatment
guidelin
herp
includ
three
antivir
therapi
acyclovir
famciclovir
valacyclovir
begin
soon
possibl
symptom
begin
antivir
therapi
may
effect
taken
onset
prodrom
symptom
ie
tinglingantivir
therapi
reduc
durat
outbreak
approxim
dayssuppress
therapi
highli
effect
dramat
reduc
frequenc
recurr
suppress
continu
year
low
risk
toxic
develop
drugresist
hsv
suppress
therapi
also
reduc
frequenc
asymptomat
hsv
shed
vzv
human
alpha
herp
viru
member
herp
famili
linear
doublestrand
dna
genometh
vzv
genom
patient
chicken
pox
primari
subsequ
latenc
follow
reactiv
viru
known
shingl
recurr
viru
spread
via
contact
vesicular
fluid
inhal
respiratori
dropletsmultipl
recurr
common
trigger
immunosuppress
exposur
cytotox
drug
radiat
malign
varicella
chicken
pox
chicken
pox
caus
vzv
one
contagi
childhood
diseas
nearli
everi
unvaccin
child
becom
infect
itmild
selflimit
ill
common
schoolag
children
fever
follow
vesicular
erupt
skin
mucou
membranesspread
respiratori
secret
day
incub
periodmor
sever
adult
pneumonia
common
herp
zoster
shingl
recurr
infect
usual
adult
may
activ
trauma
neoplasm
immunosuppressionviru
remain
latent
sensori
ganglia
spinal
cranial
nerv
caus
dermatom
pain
vesicular
erupt
fever
malais
commonli
occur
trunk
may
affect
dermatomeassoci
enceph
delay
cerebr
vascul
zoster
sine
herpet
occur
event
recurr
absenc
vesicl
formationpost
herpet
neuralgia
pain
last
longer
month
episod
occur
mani
affect
individu
particularli
year
age
neuralgia
resolv
within
one
year
experienc
resolut
within
monthsramsay
hunt
syndrom
combin
cutan
involv
herp
zoster
infect
extern
auditori
canal
ipsilater
facial
auditori
nerv
syndrom
caus
facial
paralysi
hear
deficit
vertigo
specimensskin
vesicl
fluid
cerebrospin
fluid
nasopharyng
secret
bronchial
wash
blood
amniocentesi
fluid
urin
convent
test
problem
tabl
viral
cultureconventionalviru
difficult
grow
cell
cultur
unlik
hsv
vzv
manifest
narrow
rang
hostsvir
isol
attempt
case
sever
diseas
especi
immunocompromis
personsth
best
result
obtain
vesicular
fluid
lower
yield
site
nasopharyng
secret
blood
urin
bronchial
wash
cerebrospin
fluid
diagnos
observ
cytopath
effect
cpe
induc
viru
usual
occur
week
initi
inocul
shell
vial
assaya
centrifugationenhanc
cultur
techniqu
use
obtain
rapid
sensit
cultur
resultsit
provid
result
within
day
cytologyintranuclear
inclus
bodiesmultinucl
mold
giant
cellsmargin
nuclear
chromatin
serolog
studiesenzymelink
immunosorb
assay
elisa
rang
sensit
rang
specif
latex
agglutin
la
rapid
simpl
perform
assay
detect
antibodi
vzv
glycoprotein
posit
convalescentphas
serum
posit
person
vaccin
fluoresc
antibodi
membran
antigen
fama
testit
highli
sensit
gold
standard
screen
immun
statu
posit
convalescentphas
serum
posit
person
vaccin
direct
fluoresc
antibodi
dfa
use
fluoresceinlabel
monoclon
antibodi
specif
either
hsv
vzv
antigensresult
obtain
within
sever
hoursspecimen
best
collect
base
skin
lesion
prefer
fresh
fluidfil
vesicleth
use
dfa
may
posit
viral
cultur
neg
infect
cell
viral
protein
persist
cessat
viral
replic
molecular
method
tabl
convent
pcr
target
vzv
orf
gene
detect
limit
copiesmlrealtim
pcr
vzv
lc
pcr
kit
qiagen
pcr
kit
use
identif
pathogen
includ
herp
virus
cmv
ebv
vzvharmon
amplif
profil
allow
parallel
test
four
differ
herp
virus
singl
run
instrumentsanalyt
sensit
five
copiesreactionspecif
vzv
qualit
kitit
target
orf
gene
dna
polymeras
orf
gene
orf
gene
dna
bind
proteinit
sensit
shell
vial
cell
cultur
assay
dermal
specimen
realtim
quantit
pcr
techniqueit
target
orf
gene
orf
gene
glycoprotein
bassay
result
rang
copiesml
copiesmlit
sensit
cell
cultur
dermal
specimen
pitfallsimport
note
pcr
assay
standard
variat
sampl
handl
laboratori
method
affect
sensit
assay
although
varicella
vaccin
routin
given
childhood
vaccin
certain
highrisk
group
scenario
requir
care
monitor
ie
immunocompromis
patient
intrauterin
infect
fetu
vzv
detect
pcr
test
amniocentesi
fluidit
appli
differ
specimen
includ
mucosa
secret
skin
lesion
etcdiagnosi
enceph
immunocompromis
patient
detect
vzv
csfearli
initi
vzvspecif
antivir
therapi
may
prevent
seriou
morbid
among
hivinfect
patient
human
papillomaviru
hpv
member
papillomavirida
famili
complet
integr
dna
host
cell
human
known
reservoir
hpvpapillomavirus
nonenvelop
virus
icosahedr
symmetri
capsomer
surround
genom
contain
doublestrand
circular
dna
approxim
base
pairsth
express
viral
gene
close
associ
epitheli
local
link
state
cellular
differenti
viral
gene
activ
infect
keratinocyt
leav
basal
layer
product
viru
particl
occur
highli
differenti
keratinocyt
therefor
viru
product
occur
epitheli
surfac
cell
ultim
slough
environmentov
genotyp
hpv
identifi
base
dna
sequenc
heterolog
specif
group
term
highrisk
genit
hpv
type
especi
also
recogn
necessari
factor
develop
cervic
cancerth
genom
hpv
viru
circular
fig
genom
eight
open
read
frame
encod
ten
protein
gene
divid
earli
region
express
skin
infect
basal
cell
yet
differenti
late
region
two
gene
whose
protein
product
exist
cell
cell
differenti
chang
cellular
respons
program
cell
death
apoptosi
bind
tumor
suppressor
protein
bind
inactiv
retinoblastoma
protein
rb
protein
earli
viral
protein
express
upon
infect
caus
destabil
infect
cell
induc
replicationa
cell
differenti
migrat
upward
induc
express
gene
caus
viral
replic
destabil
cytoskeleton
prevent
cellular
differentiationin
upper
epitheli
cell
layer
late
viral
protein
major
capsid
protein
minor
capsid
protein
express
bind
viral
dna
autoassembl
give
rise
complet
virion
readi
new
infect
releas
keratinocyt
desquamateth
common
mode
transmiss
via
contact
ie
sexual
autoinocul
hpv
far
common
sexual
transmit
diseas
estim
sexual
activ
adult
infect
one
genit
hpv
strain
vast
major
infect
adult
experi
transient
infect
unawar
condit
howev
may
abl
infect
othershowev
women
infect
highrisk
hpv
especi
women
year
age
develop
cervic
cancer
immun
system
effect
clear
infect
cours
sever
monthsspecif
factor
determin
hpv
infect
persist
develop
squamou
intraepitheli
lesion
current
unknown
cigarett
smoke
ultraviolet
radiat
pregnanc
folat
defici
immun
suppress
implic
possibl
cofactorslowrisk
hpv
type
produc
benign
epitheli
tumor
skin
mucou
membran
infect
certain
type
hpv
high
risk
also
increas
risk
develop
cervic
cancer
type
condit
associ
hpvverruca
vulgari
common
wart
associ
highli
contagi
spread
site
skin
mucou
membran
via
autoinoculationcondyloma
acuminatum
vener
wart
associ
consid
sexual
transmit
diseas
lesion
occur
site
sexual
contact
trauma
ie
mucou
membran
genitalia
perian
region
oral
caviti
larynx
flat
wart
commonli
found
face
forehead
common
children
teensplantar
wart
found
sole
feetsubungu
periungu
wart
form
fingernail
subungu
around
fingernail
cuticl
periungu
subtyp
common
skin
wart
may
difficult
cure
wart
locationsbutch
wart
caus
occur
peopl
handl
meat
poultri
fishfoc
epitheli
hyperplasia
heck
diseas
caus
possibl
commonli
occur
nativ
american
inuit
popul
childhood
condit
character
multipl
soft
nontend
flat
papul
plaqu
oral
mucou
membranelaryng
papillomatosi
frequent
recur
may
requir
repetit
surgeri
interfer
breath
rare
case
progress
laryng
cancer
hivassoci
papillomatosi
immunocompromis
statescerv
cancer
histori
hpv
highrisk
type
infect
strongli
associ
develop
cervic
cancer
howev
hpv
infect
progress
cervic
cancer
progress
transform
normal
cervic
cancer
cell
slow
process
cancer
occur
peopl
infect
hpv
long
time
usual
decad
highrisk
hpv
type
togeth
respons
cervic
cancer
case
type
alon
caus
cervic
cancersanalrect
cancer
although
rare
analrect
cancer
becom
preval
us
similar
cervic
cancer
main
caus
anal
cancer
hpv
commonli
acquir
anal
intercours
howev
anal
cancer
also
acquir
genit
area
infect
hpv
particularli
vulva
peni
highrisk
hpv
type
associ
anal
squamou
intraepitheli
lesion
account
approxim
cervic
anal
cancershead
neck
squamou
cell
cancer
common
type
detect
head
neck
squamou
cell
cancer
hnscc
account
hpvposit
oropharyng
case
hpv
type
account
oropharyng
oral
caviti
laryng
hpvposit
scc
genotyp
associ
better
prognosi
squamou
cell
carcinoma
head
neck
furthermor
hpvposit
tumor
also
sensit
radiat
chemotherapi
coinfect
possibl
frequent
includ
often
report
identifi
hpvposit
hnscc
numer
hpv
type
rare
detect
hnscc
includ
type
cancer
hpv
includ
may
also
caus
vulvar
nonmelanoma
skin
cancer
rare
penil
cancer
highrisk
type
hpv
caus
intraepitheli
neoplasia
abnorm
precancer
cell
growth
vulva
cervix
progress
cancer
specimen
cervic
washingsbrush
collect
liquid
media
ie
preservcyt
digen
specimen
collect
tube
hybrid
captur
biopsiesconvent
test
problemsvir
culturehpv
reliabl
cultur
identifi
use
techniqu
cytologykoilocytosi
describ
combin
perinuclear
clear
halo
pyknot
shrunken
nucleu
serolog
studi
use
diagnosi
molecular
method
genotypingnucl
acid
hybridizationin
situ
hybrid
inform
hpv
dna
test
ventana
medic
system
inc
tucson
az
use
tissu
section
liquidbas
cytolog
specimen
cervic
smearson
slide
detect
high
lowrisk
hpv
probe
cocktail
highrisk
hpv
genotyp
probe
cocktail
lowrisk
hpv
genotyp
nucleic
acid
hybridizationdigen
hybrid
captur
ii
digen
corpor
gaithersburg
md
method
util
rna
probe
mix
detect
gene
hpv
assay
identifi
hr
hpv
type
addit
kit
detect
lowrisk
viru
also
availablemanu
semiautom
rapid
captur
autom
util
qiagen
qiasymphoni
extract
system
platform
availablesign
amplif
base
immunocaptur
dnarna
hybrid
immobil
micropl
react
alkalin
phosphataseconjug
antibodi
specif
rna
dna
hybrid
detect
chemiluminesc
substratecan
detect
viral
copi
per
sampl
one
picogram
hpv
dna
per
sampl
signal
amplificationinvad
assay
cervista
hpv
assay
holog
madison
wi
invad
assay
isotherm
linear
signal
amplif
use
structurespecif
oligonucleotid
cleavag
appli
dnabas
genotyp
method
use
two
type
isotherm
reaction
primari
reaction
occur
target
dna
sequenc
secondari
reaction
produc
fluoresc
signalinvad
util
intern
control
human
assur
dna
qualiti
quantiti
reactiontwo
diagnost
qualit
assay
format
util
invad
chemistri
avail
cervista
hpv
hr
detect
pool
hpv
genotyp
cervista
detect
andor
cervista
hpv
hr
use
isotherm
signal
amplif
detect
h
hpv
type
util
three
probe
pool
base
phylogen
related
probe
pool
includ
pool
assay
determin
specif
hpv
genotyp
presentth
cervista
test
diagnost
test
genotyp
cervic
specimenscan
detect
viral
copi
per
specimen
target
amplificationtma
aptima
hpv
assay
genprob
san
diego
ca
aptima
hpv
assay
vitro
nucleic
acid
amplif
test
qualit
detect
viral
messeng
rna
mrna
highrisk
type
hpv
cervic
specimensdetect
hpv
subtyp
distinguish
highrisk
typesth
assay
use
tigri
dt
system
one
first
diagnost
instrument
truli
autom
nucleic
acid
test
nat
start
finish
sampl
prepar
amplif
detect
report
resultsth
tigri
system
process
approxim
sampl
shift
sampl
approxim
hthe
aptima
hpv
assay
involv
three
main
step
mainli
target
captur
target
amplif
transcriptionmedi
amplif
tma
detect
amplif
product
amplicon
hybrid
protect
assay
hpa
measur
emit
rel
light
unit
rlu
luminometercan
detect
viral
copi
per
sampl
realtim
pcr
hpv
test
roch
diagnost
indianapoli
coba
hpv
test
clinic
diagnost
qualit
assay
detect
hpv
patient
sampl
use
coba
system
autom
specimen
extract
amplif
detect
assay
util
amplif
hpv
dna
realtim
pcr
nucleic
acid
hybrid
detect
highrisk
hpv
genotyp
singl
reaction
tube
target
polymorph
region
hpv
genometh
assay
specif
genotyp
concurr
detect
highrisk
genotyp
pool
fashion
coba
hpv
test
base
two
major
process
autom
specimen
prepar
simultan
extract
hpv
cellular
dna
pcr
amplif
target
dna
sequencesus
hpv
complementari
primer
pair
realtim
detect
cleav
fluorescentlabel
hpv
oligonucleotid
detect
probesth
master
mix
reagent
coba
hpv
test
contain
primer
pair
probe
specif
highrisk
hpv
type
dnath
detect
amplifi
dna
amplicon
perform
thermal
cycl
use
oligonucleotid
probe
label
four
differ
fluoresc
dye
amplifi
signal
highrisk
hpv
type
detect
use
fluoresc
dye
signal
detect
dedic
fluoresc
dyean
addit
primer
pair
probe
target
human
gene
amplicon
provid
process
controlcan
detect
viral
copiesml
genotypingroch
linear
array
fig
qualit
test
util
amplif
hpv
target
dna
pcr
nucleic
acid
hybrid
base
four
major
step
sampl
prepar
pcr
amplif
target
dna
use
hpvspecif
complementari
primer
hybrid
amplifi
product
oligonucleotid
probe
colorimetr
detect
probebound
amplifi
productsus
pool
biotinyl
primer
defin
sequenc
nucleotid
region
hpv
genom
design
amplifi
hpv
dna
hpv
genotyp
includ
highrisk
genotyp
gene
concurr
isol
ensur
adequaci
cellular
extract
amplif
process
sampl
sensit
specif
overal
sensit
cytolog
detect
hgsil
rang
specif
overal
sensit
hpv
dna
test
detect
hgsil
specif
overal
sensit
coba
hpv
assay
detect
hgsil
specif
overal
sensit
cervista
hpv
assay
detect
hgsil
specif
overal
sensit
aptima
hpv
test
detect
hgsil
specif
howev
sensit
specif
influenc
age
preval
tabl
pitfallspres
avail
assay
provid
qualit
result
correl
magnitud
posit
assay
signal
meaning
quantit
resultsth
effect
potenti
variabl
vagin
discharg
use
tampon
douch
person
lubric
topic
medica
specimen
collect
variabl
may
affect
perform
assaya
neg
hpv
result
exclud
possibl
present
futur
cytolog
abnormalitiescoba
hpv
assaystrong
laboratori
inform
system
need
support
autom
bar
codinginvalid
result
frequent
aptima
hpv
assayassay
detect
mrna
hpv
lowrisk
typesperform
characterist
base
thinprep
processor
cervista
hpv
assayindetermin
test
result
caus
insuffici
mix
pipet
error
inadequ
genom
dnaexhibit
crossreact
genotyp
digen
hybrid
captur
assaylimit
sensit
pgml
mix
highrisk
lowrisk
probe
distinguish
specif
hpv
typesmanu
platform
laborintens
screen
patient
ascu
atyp
squamou
cell
undetermin
signific
pap
smear
result
determin
need
referr
colposcopi
result
test
intend
prevent
women
proceed
colposcopi
tabl
women
year
older
highrisk
hpv
dna
test
use
pap
smear
adjunct
screen
assess
presenc
absenc
highrisk
hpv
type
inform
togeth
physician
assess
cytolog
histori
risk
factor
profession
guidelin
may
use
guid
patient
manag
tabl
recent
new
test
scheme
propos
fig
influenza
part
orthomyxovirida
famili
classifi
three
basic
type
influenza
b
c
tabl
influenza
viru
type
envelop
singlestrand
rna
viru
share
structur
biolog
similar
differ
antigen
type
influenza
viru
caus
pandem
found
varieti
warmblood
anim
type
b
predominantli
human
pathogen
type
c
found
human
pigsinfluenza
virus
segment
rna
genom
fig
influenza
b
contain
eight
distinct
segment
cover
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
matrix
influenza
c
seven
segment
one
surfac
glycoprotein
virus
type
base
protein
exampl
influenza
express
hemagglutinin
neuraminidas
dynam
viru
may
evolv
two
differ
way
via
antigen
drift
antigen
shift
result
genet
divers
antigen
shift
occur
two
differ
strain
influenza
virus
combin
antigen
differ
ha
na
reassort
viral
rna
segment
process
occur
everi
year
antigen
drift
occur
random
point
mutat
viral
rna
lead
amino
acid
substitut
ha
glycoprotein
influenza
type
virus
undergo
antigen
shift
drift
influenza
type
b
virus
undergo
antigen
drifteach
influenza
rna
segment
encapsul
nucleoprotein
form
complex
surround
matrix
proteinsinfluenza
viru
infect
rank
one
common
infecti
diseas
humankind
howev
influenza
may
potenti
caus
sever
epidem
kill
averag
individu
usinfluenza
viru
infect
occur
transmiss
respiratori
secret
infect
individu
person
immunolog
susceptiblea
number
differ
subtyp
classifi
within
influenza
type
base
two
viral
surfac
protein
hemagglutinin
neuraminidas
common
prevail
human
influenza
subtyp
year
distribut
vaccin
contain
strain
along
influenza
b
strain
novel
influenza
strain
emerg
march
caus
agent
current
public
health
emergencyin
march
outbreak
influenzalik
ill
occur
mexico
us
cdc
report
seven
case
novel
influenza
preliminari
genet
character
found
hemagglutinin
gene
similar
swine
flu
virus
present
us
pig
sinc
neuraminidas
matrix
protein
gene
resembl
version
present
european
swine
flu
isol
six
gene
american
swine
flu
mixtur
swine
flu
bird
flu
human
flu
virusesrec
sever
studi
report
novel
strain
carri
promin
amino
acid
chang
posit
within
primari
hemagglutinin
receptor
bind
site
previous
enhanc
virul
associ
chang
clinic
link
sever
morbid
mortal
although
present
influenza
viru
infect
variabl
typic
symptom
may
includ
follow
fever
sore
throat
myalgia
headach
rhiniti
fatigu
cough
onset
ill
may
abruptpati
preexist
immun
receiv
vaccin
may
mild
less
sever
symptomsacut
encephalopathi
recent
describ
associ
influenza
viru
clinic
featur
includ
alter
mental
statu
coma
seizur
ataxiain
young
infant
influenza
may
produc
sepsislik
pictur
shock
occasion
influenza
virus
caus
croup
pneumoniain
april
novel
influenza
viru
identifi
mexico
sinc
spread
rapidli
worldwid
uniqu
genet
antigen
featur
viru
result
high
incid
infect
epidemiolog
profil
differ
previou
season
influenza
infect
consequ
surg
pediatr
patient
present
emerg
depart
physician
offic
across
countri
flu
seasonvomit
diarrhea
report
often
influenza
viru
infect
season
influenzath
incub
period
typic
rang
h
specimen
tabl
nasopharyng
aspirateswabwash
tracheal
aspir
bronchoalveolar
lavagetransportculturedfa
ml
minimum
ml
respiratori
sampl
viral
transport
media
microtest
steril
leakproof
contain
ml
minimum
ml
serum
sst
tube
unaccept
specimen
dri
swab
wood
calcium
algin
swab
may
inactiv
viru
cultur
plasma
hemolyz
lipem
icter
turbid
bacteri
contamin
heatinactiv
serum
inadequ
serolog
testal
respiratori
specimen
kept
longer
h
test
ideal
test
within
h
collect
storag
longer
h
necessari
clinic
specimen
store
freez
higher
temperatur
eg
reduc
likelihood
viru
detect
convent
test
problem
tabl
viral
cultureth
criterion
standard
diagnos
influenza
b
via
viral
propag
embryon
hen
egg
canin
kidney
mdck
cellslaboratori
diagnosi
influenza
establish
specif
cytopath
effect
observ
hemadsorpt
test
find
positiveaft
cultur
isol
final
identif
via
immunoassay
immunofluorescencestain
infect
cultur
cell
line
fluoresc
antibodi
confirm
diagnosisth
viral
cultur
process
requir
day
completeprimari
method
vaccin
product
dfa
testingdfa
wide
avail
variabl
sensit
rang
influenza
viru
high
specif
dfa
detect
distinguish
influenza
b
virus
distinguish
among
differ
influenza
subtypesth
techniqu
rapid
h
result
less
sensit
cultur
method
serolog
studiestwo
sampl
collect
per
person
one
sampl
within
first
week
acut
symptom
second
sampl
convalesc
week
later
antibodi
level
increas
first
second
sampl
influenza
infect
like
occurredbecaus
length
time
need
diagnosi
influenza
serolog
test
diagnost
test
use
rapid
diagnosi
neededin
differenti
current
previou
infect
use
rapid
diagnosi
rapid
influenza
diagnost
test
ridt
tabl
ridt
wide
avail
variabl
sensit
rang
detect
influenza
compar
realtim
revers
transcriptas
polymeras
chain
reaction
rrtpcr
neg
ridt
result
rule
influenza
viru
infectionridt
high
specif
depend
commerci
avail
ridt
use
test
either
detect
distinguish
influenza
b
virus
detect
influenza
b
distinguish
influenza
b
virusesfastest
method
current
avail
diagnost
tool
result
may
obtain
minhowev
techniqu
sensit
molecular
method
tabl
gener
informationnucl
acid
amplif
test
includ
rrtpcr
sensit
specif
influenza
diagnost
testsbut
may
readili
avail
obtain
test
result
may
take
one
sever
day
test
perform
depend
individu
rrtpcr
assay
assay
fals
neg
occurnot
nucleic
acid
amplif
assay
specif
differenti
influenza
viru
influenza
virusessever
rrtpcr
assay
evalu
author
fda
emerg
use
author
eua
diagnos
influenza
viru
infect
roch
realtimereadi
influenza
test
cepheid
flu
panel
diagnosi
influenza
viru
infect
elitech
molecular
diagnost
influenza
viru
realtim
rtpcr
test
focu
diagnost
influenza
realtim
rtpcr
imdx
influenza
realtim
rtpcr
assay
intelligentmdx
qiagen
influenza
lc
rtpcr
kit
rtpcr
influenza
lc
rtpcr
kit
qiagen
diagnost
assay
detect
influenza
viral
rna
detect
differenti
influenza
viru
rna
nasopharyng
swab
symptomat
patientsth
assay
util
advanc
instrument
dsp
viru
card
v
qiagen
dsp
viru
kit
qiagen
viral
nucleic
acid
extract
lightcycl
instrument
softwar
v
roch
use
amplif
detectionth
limit
detect
influenza
season
tcid
tissu
cultur
infecti
dose
ml
limit
detect
influenza
pfu
plaqueform
unit
ml
rtpcr
cepheid
flu
panel
asr
accur
detect
differenti
influenza
influenza
b
infect
simultan
identif
flu
strainless
minut
handson
time
improv
lab
workflow
efficienciesaccept
nasal
aspiratewash
naw
nasopharyng
np
swab
accommod
wide
rang
specimen
type
rtpcr
roch
realtimereadi
influenza
detect
setin
midnovemb
test
receiv
emerg
use
author
eua
us
fdath
test
influenza
viru
detect
rna
influenza
viru
provid
rapid
mean
identif
patient
infect
viru
durat
declar
emerg
influenza
antivir
resist
testin
us
four
antivir
drug
fda
approv
use
influenza
amantadin
rimantadin
zanamivir
oseltamivir
adamantan
drug
amantadin
rimantadin
approv
influenza
neuraminidas
inhibitor
drug
zanamivir
oseltamivir
approv
influenza
influenza
bto
date
influenza
influenza
influenza
b
virus
detect
surveil
three
viru
strain
typic
sensit
oseltamivir
zanamivir
influenza
strain
resist
adamantan
sporad
oseltamivirresist
influenza
viru
infect
identifiedth
oseltamivirresist
influenza
commonli
describ
point
mutat
viru
neuraminidas
gene
histidin
tyrosin
posit
neuraminidas
commonli
refer
number
known
confer
highlevel
resist
oseltamivirinfluenza
virus
carri
mutat
reduc
abil
replic
transmit
effici
compar
parent
suscept
viru
clinic
implic
infect
virus
larg
unknownrtpcr
along
sequenc
sanger
sequenc
next
gen
sequenc
pyrosequ
usual
use
influenza
antivir
resist
test
sensit
specificitysensit
dfa
methodolog
depend
upon
adequaci
specimen
ie
cell
otherwis
specimen
may
inadequ
accur
interpret
result
fals
negativesrapid
diagnost
test
approxim
sensit
detect
influenza
approxim
specif
thu
mani
sampl
would
posit
influenza
viral
cultur
may
give
neg
rapid
test
result
rapid
test
result
may
indic
influenza
person
infect
influenza
pitfallsdu
length
time
requir
perform
viral
cultur
assay
poor
efficaci
result
obtain
much
patient
left
offic
well
past
time
drug
therapi
could
effectivedevelop
pcrbase
assay
must
alway
consid
antigen
drift
random
mutat
due
viral
evolut
may
result
fals
neg
cost
avail
sensit
issu
diagnosi
influenza
often
base
clinic
criteria
presentationrtpcr
assay
provid
rapid
specif
diagnosi
influenza
allow
earli
therapeut
intervent
prophylact
treatment
highrisk
patient
ie
geriatr
care
facilitymolecular
diagnosi
play
larg
role
epidemiolog
surveil
vaccin
strain
select
surveil
emerg
novel
influenza
virus
ie
hong
kong
outbreak
sequenc
analysi
influenza
virus
infect
bird
call
avian
influenza
virus
commonli
known
bird
flu
influenza
virus
subtyp
infect
birdsther
substanti
genet
differ
subtyp
typic
infect
peopl
bird
within
subtyp
avian
influenza
virus
also
differ
strainsth
incub
period
avian
influenza
viru
typic
day
long
daysthes
influenza
virus
occur
natur
among
birdswild
bird
worldwid
carri
virus
intestin
usual
get
sick
themhowev
avian
influenza
contagi
among
bird
make
domest
bird
includ
chicken
duck
turkey
sick
kill
mani
differ
subtyp
type
influenza
virus
fig
subtyp
differ
chang
certain
protein
surfac
influenza
viru
hemagglutinin
neuraminidas
protein
known
hemagglutinin
subtyp
known
neuraminidas
subtyp
influenza
virusesmani
differ
combin
hemagglutinin
neuraminidas
protein
possibl
combin
repres
differ
subtypeavian
influenza
virus
distinguish
low
pathogen
high
pathogen
form
basi
genet
featur
viru
sever
ill
caus
poultri
influenza
viru
identifi
low
pathogen
formeach
three
avian
influenza
virus
theoret
partner
one
nine
neuraminidas
surfac
protein
thu
potenti
nine
differ
form
subtyp
eg
report
sign
symptom
avian
influenza
human
rang
eye
infect
conjunct
influenzalik
ill
symptom
eg
fever
cough
sore
throat
muscl
ach
sever
respiratori
ill
eg
pneumonia
acut
respiratori
distress
viral
pneumonia
sometim
accompani
nausea
diarrhea
vomit
neurolog
changescdc
recommend
oseltamivir
prescript
antivir
medic
treatment
prevent
human
infect
avian
influenza
virus
analys
avail
virus
circul
worldwid
suggest
virus
suscept
oseltamivir
howev
evid
resist
oseltamivir
report
virus
isol
human
case
monitor
antivir
resist
among
avian
influenza
virus
import
ongoingth
first
avian
influenza
viru
infect
human
occur
hong
kong
epidem
link
chicken
classifi
avian
influenza
human
case
avian
influenza
sinc
report
asia
africa
europ
indonesia
vietnam
pacif
near
east
hundr
peopl
becom
sick
viru
slightli
becam
ill
die
specimen
see
influenza
b
c
sectionvir
cultur
see
influenza
b
c
sectionserolog
test
see
influenza
b
c
sectionmolecular
testrealtim
rtpcron
februari
fda
announc
clearanc
influenza
asian
lineag
viru
realtim
rtpcrprimer
probe
set
inactiv
viru
sourc
posit
rna
control
vitro
qualit
detect
highli
pathogen
influenza
viru
asian
lineag
two
genet
lineag
influenza
virus
exist
eurasian
asian
north
american
primer
probe
set
develop
cdc
design
detect
highli
pathogen
influenza
virus
asian
lineag
associ
recent
laboratoryconfirm
infect
avian
influenza
human
east
asia
recent
turkey
iraqth
test
limit
laboratori
design
laboratori
respons
network
lrn
consist
approxim
us
laboratori
state
limitationdu
limit
assay
neg
result
preclud
influenza
viru
infect
use
sole
basi
treatment
patient
manag
decis
adenoviru
ubiquit
human
endemicadenovirus
mediums
nm
nonenvelop
icosahedr
virus
contain
doublestrand
dna
fig
least
known
immunolog
distinct
type
seven
subgenera
caus
human
infect
type
common
militari
recruit
outbreak
type
commonli
associ
sever
sometim
fatal
respiratori
illnessesadenoviru
transcript
defin
twophas
event
earli
late
occur
dna
replicationearli
transcript
accompani
complex
seri
splice
event
four
earli
cassett
gene
term
earli
gene
facilit
dna
replic
result
transcript
translat
late
gene
fig
adenoviru
produc
cytolysi
differ
tissu
induc
host
inflammatori
respons
cytokin
productionth
rout
entri
usual
droplet
nuclei
oral
infect
transmiss
adenoviru
via
direct
contact
rout
occasion
waterborn
adult
measur
titer
antiadenoviru
antibodi
impli
prior
infect
adenoviru
infect
occur
earli
life
age
children
infect
least
one
serotyp
howev
infect
asymptomaticsom
adenoviru
type
establish
persist
subclin
infect
tonsil
adenoid
intestin
infect
host
viral
shed
occur
long
sever
month
yearsadenoviru
may
infect
multipl
organ
system
recogn
etiolog
agent
varieti
divers
syndrom
acut
respiratori
diseas
ard
pharyngoconjunctiv
fever
epidem
keratoconjunct
acut
hemorrhag
cystiti
gastroenter
adenovir
infect
immunocompromis
hostsinfect
serotyp
frequent
first
year
life
serotyp
occur
season
infect
frequent
late
winter
earli
spring
histor
respiratori
infect
caus
adenoviru
preval
adenoviru
respiratori
infect
children
rang
adenoviru
also
caus
acut
diarrheal
infect
children
specimensrespiratori
stool
blood
convent
test
problemsvir
cultureth
gold
standard
adenoviru
test
viral
culturecollect
sampl
layer
monolay
cell
test
tube
present
adenoviru
present
cytopath
effect
round
cellsth
best
cell
line
test
adenoviru
human
carcinoma
continu
cell
linewhen
sampl
collect
within
day
clinic
onset
cell
cultur
gener
posit
within
day
sampl
collect
day
may
take
week
produc
cytopath
effectslow
growth
ideal
acut
identif
viral
cultur
confirm
adenoviru
diagnosi
may
provid
time
result
immedi
patient
care
shell
vial
cultureshel
vial
anoth
cell
cultur
test
result
readi
daysvial
cell
inocul
collect
sampl
centrifug
vial
incub
stain
day
three
immunofluoresc
antibodi
specif
adenovirusth
cell
infect
adenoviru
light
examin
fluoresc
microscopeit
recommend
shell
vial
test
diagnos
ocular
adenoviru
infect
serolog
studiesseroreact
adenoviru
common
measur
adenovirusspecif
igm
rise
level
igg
antibodi
help
posit
adenoviru
titer
occur
individu
year
oldserolog
less
use
acut
clinic
settingfor
serolog
diagnosi
serum
obtain
earli
possibl
clinic
cours
follow
second
titer
week
later
rise
acut
titer
convalesc
titer
diagnosticserolog
assay
use
year
measur
adenovirusspecif
igm
rise
level
igg
antibodi
howev
serolog
longer
diagnosi
slow
less
specif
antigen
dna
detect
immunofluorescencedfa
indirect
ifa
may
use
direct
examin
tissu
use
mous
antibodi
adenoviru
groupspecif
hexon
antigenthi
method
shown
poor
sensit
compar
test
shell
viral
cultur
run
concurr
improv
sensitivitysever
commerci
kit
light
ifa
dfa
respiratori
viral
screen
kit
respiratori
syncyti
viru
rsv
flu
b
parainfluenza
adenovirus
millipor
corp
rsv
flu
b
parainfluenza
adenovirus
biorad
laboratori
molecular
methodspcr
mark
improv
sensit
compar
viral
culturemost
assay
amplifi
conserv
region
hexon
genemost
realtim
quantit
pcr
design
detect
adenoviru
dna
major
subgroup
virusfour
common
multiplex
assay
multicodeplx
assay
eragen
resplex
iii
assay
millipor
adenoviru
ce
mark
pcr
assay
detect
quantifi
adenoviru
serotyp
xtag
rvp
assay
luminex
molecular
diagnost
xtag
rvp
fdaapprov
test
report
sensit
specif
pitfallsdevelop
pcrbase
assay
must
alway
consid
antigen
drift
random
mutat
due
viral
evolut
may
result
fals
negativesimport
note
pcr
assay
standard
variat
sampl
handl
laboratori
method
affect
sensit
assay
pcr
assay
provid
rapid
specif
diagnosi
adenoviru
allow
earli
therapeut
intervent
prophylact
treatment
highrisk
patient
ie
geriatr
care
facil
immunocompromis
patientsdetect
high
viral
load
blood
monitor
viral
load
treatment
correl
dissemin
adenoviru
diseas
immunosuppress
patient
adenoviru
increasingli
import
solid
organ
bone
marrow
transplant
patient
infect
pediatr
transplant
case
exceed
mortal
rate
high
rsv
neg
sens
envelop
rna
viru
virion
variabl
shape
size
nm
unstabl
environ
surviv
hour
environment
surfac
readili
inactiv
soap
water
disinfectantsrsv
member
paramyxoviru
famili
produc
characterist
fusion
human
cell
syncyti
effect
tissu
culturersv
mediums
envelop
viru
antisens
singlestrand
rna
genomersv
two
heterotyp
strain
virus
antigen
distinct
classifi
subgroup
bthe
major
differ
subgroup
antigen
properti
g
surfac
glycoproteintransmiss
aerosol
respiratori
droplet
via
close
contact
infect
person
contact
contamin
surfacesmost
preval
infant
age
month
children
age
underli
cardiac
pulmonari
diseas
immunocompromis
risk
seriou
complic
rsv
infect
rsv
infect
typic
occur
temper
climat
late
fall
earli
spring
account
communityacquir
pneumonia
children
infect
infect
year
immun
wane
age
diseas
may
reoccur
patient
yearstwo
subtyp
identifi
subtyp
involv
sever
clinic
present
predomin
outbreak
subtyp
b
predomin
asymptomat
strain
viru
major
popul
experiencesrsv
bronchiol
present
prodrom
phase
resembl
common
viral
upper
respiratori
tract
infect
addit
symptom
includ
rhinorrhea
wheez
cough
lowgrad
fever
pneumonia
circumor
nail
bed
cyanosi
may
occur
sever
affect
infantsin
major
patient
rsv
bronchiol
symptom
resolv
within
day
specimen
respiratori
swab
bronchoalveolar
lavageconvent
test
problemsvir
culturersv
high
liabil
specimen
transport
laboratori
promptli
inocul
cell
culturesnasopharyng
aspir
nasal
wash
tracheal
secret
gener
best
specimen
isolationspecimen
subject
major
temperatur
chang
freez
thawinghuman
heteroploid
cell
hela
gener
provid
best
tissu
cultur
isol
rsvrsv
produc
characterist
cpe
consist
syncytia
format
appear
daysdecreas
sensit
adult
reduc
viral
shed
acut
infect
compar
adolesc
rapid
antigen
detectiondirect
indirect
immunofluoresc
methods
perform
direct
screen
low
costboth
direct
indirect
util
either
polyclon
monoclon
antibodi
avail
possess
high
degre
sensit
specificityth
gener
sensit
monoclon
antibodi
specif
least
techniqu
fast
easi
perform
interpret
result
subject
specimen
must
contain
adequ
nasopharyng
cellsincorrect
indetermin
result
may
occur
specimen
epitheli
cell
nonspecif
antibodi
reagent
use
elisa
bd
rsv
elisa
assay
requir
expens
laboratori
equip
take
min
inexpens
compar
cell
cultureelisa
techniqu
offer
advantag
object
interpret
speed
possibl
screen
larg
number
specimen
disadvantag
includ
gener
poorer
sensit
gray
zone
equivoc
result
requir
confirm
timeconsum
block
elisa
procedur
serologyacut
convalesc
phase
sera
requir
serolog
diagnosi
rsva
fourfold
increas
antibodi
titer
appear
specif
igm
antibodi
requir
serolog
confirm
infectionit
includ
complement
fixat
cf
antibodi
titer
elisa
neutral
specif
b
subtyp
indirect
ifit
unlik
help
manag
patient
length
time
requir
furthermor
serolog
respons
young
infant
may
poor
detect
antibodi
assaysseroconvers
occur
least
week
may
requir
week
cft
less
sensit
neutral
elisa
assay
molecular
methodsnasbabeaconnuclisen
easyq
rsv
b
assay
realtim
pcrbase
assay
util
nasba
technolog
contain
intern
control
specif
molecular
beacon
mix
target
fusion
protein
rsvlimit
detect
input
copi
rsvimprov
time
result
h
cepheid
system
rsv
asr
rsv
type
b
primer
asr
contain
primer
design
detect
rsv
type
bthe
rsv
type
b
probe
asr
contain
famlabel
probe
design
detect
rsv
type
b
respiratori
viral
panel
rvp
luminex
rvp
qualit
nucleic
acid
multiplex
test
intend
simultan
detect
identif
multipl
respiratori
viru
nucleic
acid
nasopharyng
swab
individu
suspect
respiratori
tract
infectionsth
xtag
rvp
design
simultan
probe
viral
target
singl
patient
specimen
influenza
influenza
subtyp
influenza
subtyp
influenza
b
rsv
subtyp
rsv
subtyp
b
parainfluenza
parainfluenza
parainfluenza
human
metapneumoviru
rhinoviru
adenoviru
virus
probe
singl
multiplex
reactionxtag
rvp
incorpor
multiplex
revers
rtpcr
multiplex
targetspecif
primer
extens
tspe
luminex
molecular
diagnost
proprietari
univers
tag
sort
system
luminex
xmap
platform
xtag
rvp
compat
luminex
system
sensit
specificityimprov
sensit
specif
compar
convent
test
particularli
adult
populationno
crossreact
shown
influenza
b
measl
adenoviru
type
hmpv
indic
assay
specif
rsv
pitfallsalthough
rsv
viru
cultur
infect
individu
delay
definit
diagnosi
day
decreas
clinic
util
eas
assay
rapid
turnaround
time
improv
sensit
enhanc
clinic
util
earli
detect
respiratori
ill
sever
acut
respiratori
syndrom
sar
recent
identifi
respiratori
ill
first
infect
individu
part
asia
north
america
europ
late
earli
sarsassoci
coronaviru
belong
coronavirida
famili
famili
larg
envelop
positivestrand
rna
virus
first
exampl
coronaviru
caus
seriou
diseas
humansth
sarscoronaviru
sarscov
genom
nucleotid
length
gc
residuessar
spread
mainli
contact
infect
saliva
droplet
cough
vertic
transmiss
mother
infant
appear
occur
sar
viru
produc
atyp
pneumonia
often
lead
respiratori
failur
pulmonari
edema
hyalin
membran
format
similar
seen
adult
respiratori
distress
syndrom
ard
earli
phase
diseas
fever
greater
hallmark
symptom
find
often
associ
myalgia
rigor
flulik
symptomsdur
second
week
patient
develop
dri
nonproduct
cough
short
breath
lung
infiltr
rapid
progress
respiratori
distressth
caus
death
respiratori
failur
best
predictor
mortal
old
age
fatal
sar
less
peopl
age
younger
ventil
effect
treatment
current
avail
specimensrespiratori
sampl
nasal
wash
nasopharyng
swab
bal
bronchial
wash
sputumtransport
ml
minimum
volum
adult
pediatr
respiratori
sampl
viral
transport
media
microtest
steril
leakproof
contain
condit
dri
swab
accept
respiratori
aspir
collect
contain
tube
sampl
tend
leak
compromis
specimen
convent
test
problemsvir
culturerequir
facilitydifficulti
cultur
viru
infect
individu
late
outbreak
late
stage
ill
due
possibl
genet
drift
viru
serolog
studiesutil
serolog
test
poor
due
late
seroconvers
infect
patient
ie
weeksantigen
detect
monoclon
antibodi
monospecif
polyclon
antibodi
n
protein
found
sensit
specif
test
diagnosi
sarsfor
antibodi
test
indirect
immunofluoresc
antibodi
test
commonli
perform
neutral
antibodi
test
sinc
former
involv
minim
manipul
infecti
viru
therefor
carri
less
risk
biohazard
test
gener
use
first
week
ill
molecular
methodsrtpcrmultipl
rtpcr
assay
develop
detect
sar
rna
clinic
specimen
util
nest
nonnest
onestep
twostep
convent
realtim
rtpcr
assaysmost
nucleic
acid
amplif
test
design
nucleoprotein
gene
latter
gene
theoret
advantag
abund
infect
cell
therefor
higher
sensit
clearli
proven
clinic
studieslightcycl
sarscov
quantit
kit
roch
diagnost
corpor
use
lightcycl
instrumentreadi
use
amplifi
target
sequenc
replicas
gene
sar
covth
analyt
sensit
sarscov
test
copiespcr
reaction
realart
hpacoronaviru
rtpcr
kit
artu
use
lightcycl
instrument
abi
prism
instrumentsamplifi
region
sarscov
genom
eragen
bioscienc
multicodertx
research
eragen
platform
increas
size
genet
alphabet
two
dna
base
pair
six
pair
develop
eight
new
synthet
basesit
new
multiplex
realtim
pcr
platformonli
standard
pcr
primer
need
design
sinc
report
place
directli
onto
primer
probesit
target
nucleocapsid
nuc
polymeras
pol
gene
sensit
specificitysensit
commerci
assay
rang
specif
rang
absolut
sensit
rtpcr
assay
rang
genom
equival
per
reaction
pitfallswhen
present
sar
antibodi
detect
serum
point
cours
diseas
howev
patient
seroconvert
second
week
highlight
import
rtpcr
assay
earli
diagnosi
virusposit
result
must
confirm
repeat
test
use
aliquot
origin
specimen
andor
anoth
laboratori
report
altern
test
second
gene
region
may
help
furthermor
test
one
sampl
singl
sourc
rule
presenc
sarsassoci
coronavirusa
neg
result
rule
sar
presenc
pcr
inhibitor
patient
specimen
poor
rna
qualiti
nucleic
acid
concentr
level
detect
assay
may
occur
first
week
serum
plasma
prefer
rtpcr
week
sampl
type
less
effect
stool
respiratori
sampl
prefer
type
week
stool
prefer
sampl
type
rtpcr
viral
load
upper
respiratori
tract
fece
low
first
day
infect
peak
approxim
day
illnessdur
day
ill
high
viral
load
independ
predictor
poor
clinic
outcom
enterovirus
repres
one
common
human
virus
affect
estim
million
individu
us
potenti
one
billion
worldwid
enteroviru
infect
commonli
occur
temper
zone
summer
earli
fallenterovirus
divers
group
small
nonenvelop
ssrna
virus
kb
transmit
rout
enterovirus
compris
group
human
virus
includ
poliovirus
echovirus
coxsacki
virus
coxsacki
b
virus
variou
enteroviru
subtyp
origin
classif
human
enterovirus
substitut
taxonom
scheme
base
molecular
biolog
properti
virus
revis
classif
recogn
least
subtyp
separ
four
speciessever
mode
transmiss
exist
virus
includ
respiratori
transplacent
perinat
selfinocul
mode
major
enterovirus
undergo
rapid
replic
gi
tract
rare
caus
signific
gi
diseas
instead
travel
via
bloodstream
target
organ
replic
induc
patholog
alter
infect
subclin
although
may
caus
varieti
acut
chronic
diseasesacut
mild
upper
respiratori
ill
common
cold
febril
rash
hand
foot
mouth
diseas
herpangina
asept
mening
pleurodynia
enceph
acut
flaccid
paralysi
neonat
sepsislik
diseasechron
myocard
cardiomyopathi
type
diabet
mellitu
neuromuscular
diseas
highest
incid
enteroviru
infect
infant
young
children
specimensnon
steril
site
nasalthroat
swab
fece
presenc
viru
might
mere
indic
coincident
carriagesteril
site
vesicular
fluid
csf
serum
urin
gather
autopsi
reliablesampl
transport
viral
transport
media
either
transport
directli
laboratori
store
maximum
convent
test
problemsvir
cultur
shell
vial
culturegold
standard
detect
enterovirustimeconsum
method
insensit
method
reli
presenc
viabl
virusin
fulli
character
enteroviru
strain
associ
late
inadequ
collect
handl
process
sampl
intrins
insensit
cell
line
usedit
take
day
cpe
appear
viru
present
low
titer
eg
csf
specimen
type
coxsackieviru
grow
cell
culturealthough
shell
vial
cultur
use
monoclon
antibodi
decreas
cultur
time
compar
tube
cultur
less
sensit
convent
cultur
serologyserotyp
usual
irrelev
individu
managementth
absenc
wide
share
antigen
hamper
develop
immunoassay
enterovirusreport
monoclon
antibodi
crossreact
multipl
enteroviru
serotyp
promis
test
requir
determin
clinic
relev
observ
molecular
methodsr
time
rtpcr
abi
prism
appli
biosystem
foster
citi
calif
improv
speed
accuraci
use
taqman
assay
platformtarget
conserv
sequenc
ntr
vp
capsid
protein
ntr
highli
conserv
region
involv
viral
protein
translat
fig
enteroviru
realtim
taqman
pcr
analysi
serum
plasma
may
good
altern
enteroviru
cultur
fece
particularli
neonat
sepsi
enteroviru
real
time
rtpcr
kitth
kit
screen
assay
detect
enterovirus
coxsacki
coxsacki
b
echoviru
capillari
system
lightcycl
roch
target
conserv
sequenc
ntr
cepheid
systemit
detect
region
ntr
nasbanasbaelectrochemiluminesc
ecl
nasbabeacon
significantli
differ
sensit
specificitytarget
conserv
sequenc
nasbaeclnuclisen
basic
kit
prove
equal
greater
sensit
detect
enterovirusesin
nuclisen
basic
kit
amplifi
rna
product
detect
hybrid
use
ecllabel
probe
highli
sensit
methodolog
nasbabeaconnuclisen
easyq
enteroviru
test
biomerieux
durham
nc
util
realtim
molecular
beacon
probe
nasbabeacon
realtim
rtpcr
use
taqman
shorten
technic
handson
time
time
result
enteroviru
consensu
argen
biosoft
research
use
us
onestep
rtpcr
enteroviru
serotyp
one
singl
reaction
tubeamplifi
region
ncr
genomedetect
perform
biotinyl
enteroviru
gener
probe
sensit
specificitynasbaecl
nasbabeacon
similar
sensit
respectivelyrtpcr
sensit
cultur
sensit
realtim
rtpcr
sensit
specif
pitfallsparechovirus
may
caus
similar
clinic
ill
detect
enteroviru
testingpoor
handl
csf
csf
collect
late
infect
yield
falseneg
resultsenterovirus
shed
high
titer
stool
prolong
period
therefor
posit
result
stool
alon
may
correl
current
diseas
enterovir
mening
common
us
lead
larg
number
hospit
per
year
due
inabl
distinguish
bacteri
mening
therefor
enteroviru
differenti
bacteri
ill
significantli
reduc
hospit
antimicrobi
use
diagnost
testingrar
dual
infect
enterovir
bacteri
occur
therefor
posit
enteroviru
result
clinic
featur
incompat
benign
viral
mening
lead
discontinu
antibiot
bk
viru
bkv
jc
viru
jcv
small
nonenvelop
close
circular
doublestrand
dna
viru
belong
human
polyomavirus
member
papovavirida
familythey
first
isol
name
jc
bk
initi
patient
first
discov
jcv
isol
brain
tissu
patient
progress
multifoc
leukoencephalopathi
pml
bkv
isol
urin
renal
transplant
patient
develop
ureter
stenosi
postoperativelybkv
jcv
share
homolog
level
nucleotid
sequenc
homolog
simian
viru
belong
polyomavirus
introduc
human
popul
contamin
polio
vaccin
produc
monkey
cellsth
two
crossreact
serolog
serolog
test
antibodi
abl
distinguish
bkv
jcvmore
adult
popul
antibodi
bkv
jcv
primari
infect
typic
occur
childhoodaft
initi
infect
polyomavirus
establish
latenc
variou
tissu
primari
site
latenc
uroepitheli
cell
bk
viru
b
lymphocyt
renal
tissu
jcv
addit
site
latenc
virus
includ
uret
brain
spleen
bkv
jcv
associ
human
tumor
recent
evid
may
cofactor
etiolog
specif
human
tumor
type
rais
interest
two
human
polyomavirus
possibl
agent
involv
human
oncogenesisin
immunocompet
individu
primari
bkv
infect
usual
caus
mild
respiratori
ill
rare
cystiti
wherea
primari
jcv
infect
typic
asymptomat
bkv
seropreval
peak
age
year
oldreactiv
latent
well
primari
bkv
jcv
infect
may
occur
immunocompromis
individu
ie
organ
transplant
aid
leukemia
bkv
infect
lead
interstiti
nephriti
tubul
hemorrhag
cystiti
kidney
allograft
rejectionjcv
respons
progress
multifoc
leukoencephalopathi
pml
fatal
demyelin
diseas
central
nervou
system
seen
aid
patient
specimen
urin
plasma
csf
tissu
biopsyconvent
test
problemscytolog
immunohistocytochemistri
urin
sampleit
use
confirm
bkv
reactiv
diagnosisth
urin
sampl
stain
jcbk
monoclon
antibodi
viral
culturejc
viru
difficult
cultureth
sensit
cell
type
jcv
primari
human
fetal
glial
cell
easi
reagent
acquirebk
viru
grow
common
cell
line
human
diploid
fibroblast
sever
day
week
requir
cpe
evid
serolog
studieshemagglutin
inhibit
enzymelink
immunosorb
assay
method
measur
titer
antibodi
jcv
bkvserolog
test
blood
csf
antijcv
bkv
antibodi
use
diagnosi
pml
immunosuppress
individu
antibodi
jcv
bkv
common
mani
patient
pml
immunosuppress
patient
fail
develop
signific
rise
antivir
antibodi
titer
serum
csf
molecular
method
fig
pcr
quantitativeseminest
pcr
measur
serum
bkv
dna
shown
higher
specif
posit
predict
valu
detect
bkv
nephropathi
also
shown
sensit
detect
bkv
nephropathyseri
quantif
bkv
dna
level
pcr
aid
manag
bkv
nephriti
measur
increas
decreas
activ
level
noninvasivelypcr
analysi
jcv
dna
spinal
fluid
noninvas
method
detect
activ
jcv
infect
specif
sensitivejcbk
consensu
complet
kit
argen
biosoft
us
research
use
kit
detect
type
jc
bk
virus
pcr
hybrid
microwel
plate
offer
high
sensit
copi
per
pcr
bkv
copi
per
pcr
jcv
primersprob
product
design
amplifi
jcvbkv
use
nucleas
realtim
assay
target
sequenc
correspond
fragment
bp
locat
gene
larg
antigenrealtim
taqman
pcr
lightcycl
probe
homebrew
target
highli
conserv
sequenc
jcvbkv
genom
gene
sensit
specificityanalyt
specif
crossreact
hsv
famili
virus
simian
viru
adenoviru
hiv
absolut
sensit
jcbk
viru
detectionpcr
abl
detect
jcv
csf
pml
patientsth
specif
diagnosi
influenc
choic
primer
extract
method
approach
pitfallssequ
variat
polyomaviru
genom
within
variou
jcbk
subtyp
may
caus
difficulti
primer
probe
designcompetit
jc
bk
virus
due
sensit
may
lead
falseneg
pcr
result
detect
viru
pcr
may
indic
activ
infect
therefor
identif
viral
dna
may
warrant
institut
antivir
therapi
andor
decreas
immunosuppress
therapiesdetermin
viral
dna
presenc
concentr
transplant
patient
use
establish
caus
allograft
reject
viral
load
may
also
use
immunocompromis
patientsbkv
nephropathi
associ
bk
viremia
copiesml
plasma
bk
viremia
copiesml
seen
approxim
kidney
transplant
recipientsthough
latenc
typic
associ
absenc
viremia
low
level
copiesml
plasma
seen
asymptomat
individu
two
variant
b
type
b
common
primari
infect
us
japan
europetyp
common
among
asymptomat
children
africa
nearli
popul
infect
year
ageviru
becom
latent
persist
reactiv
immunocompromis
host
present
mononuclear
cell
saliva
central
nervou
popul
show
vertic
transmissioncongenit
infect
also
report
infant
develop
undifferenti
febril
present
roseola
infantumhigh
fever
follow
maculopapular
rash
face
neck
trunkfebril
seizur
common
neurolog
complicationenceph
encephalopathi
also
report
reactiv
present
fever
rash
encephalitisdifferenti
reactiv
latent
infect
difficult
especi
follow
stem
cell
organ
transplant
specimen
isol
peripher
blood
mononuclear
cellsconvent
test
problemsserolog
testingprimari
infect
caus
igm
spike
first
week
ill
follow
igg
rise
approxim
week
later
igg
antibodi
persist
indefinitelytest
includ
indirect
immunofluoresc
immunoblot
enzym
immunoassay
viral
cultur
also
use
timeconsuminghowev
gap
onset
infect
rise
titer
allow
time
diagnosi
molecular
methodspcrqualit
nest
polymeras
chain
reactioncan
perform
plasma
mononuclear
cell
whole
blood
saliva
urin
cervic
swab
placentastudi
shown
result
plasma
show
sensit
diagnos
reactiv
primari
infect
sensitivityaddit
dna
detect
absenc
viral
replicationspecif
report
compar
viral
cultur
rtpcrincreas
sensit
specif
respect
quantit
pcrviral
load
may
helpfulprimari
infect
usual
rang
log
genom
equival
copi
gec
pbmcsasymptomat
individu
lower
viral
load
individu
latent
infect
overlap
immunocompromis
host
howev
plasma
use
distinguish
two
latent
individu
plasma
posit
viral
dna
viral
load
separ
high
integr
viru
intermedi
primari
reactiv
integr
viru
low
latent
infect
pitfallssom
overlap
occur
latent
immunocompromis
host
list
contamin
issu
given
techniqu
use
signal
amplif
especi
danger
immunocompromis
present
larg
percentag
popul
individu
greater
year
age
test
requir
determin
host
primari
latent
infectionstandard
test
viral
captur
serolog
timeconsumingquantit
pcr
rtpcr
especi
use
